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P R E F A C E.
(i )
The discovery o f  any new method o f  treatment raises problems 
o f wide variety, often, i t  might seem, unrelated to the original 
discovery. The c lin ic ia n 's  p a rt,is  the most clearly defined: he
must apply the new remedies to the disease in men. In addition, but 
o f  equal importance, he should try to assess their real value and 
measure their lim itations. The present studies relate an attempt 
to modify the course o f  two diseases by the use o f chemicals o f  the 
sulphonamide series. The extent o*f this modification has been 
measured by observing their ab ility  to control certain features 
characteristic o f  the natural behaviour o f  the "untouched” disease. 
Such a method o f  tida l has disclosed certain irregu larities  in the 
e fficiency  o f the drugs. I t  i s  a principal hypothesis o f the work 
that these irregu larities  indicate that the action o f  the drugs, in 
man, cannot be defined in simple chemical terms tut that they demand 
from the treated individual the most active support o f  some element 
o f his tissue defences other than the already well-recognised immune 
bodies.
In 1936, Dr. W.R. Snodgrass invited me to take part in testing 
the new drug "Prontosil Red” in human streptococcal in fections. Plans 
were accordingly la id  for  it s  use in the treatment o f  erysipelas, and 
during the next three years further tr ia ls  o f drugs derived from the 
original one wrere conducted. Although the therapeutic experiments 
in this disease have their individual value, i t  must be appreciated 
that this disease had lo s t  much o f the malignity that had attached to 
i t  one hundred years ago. (The introductory page contains a /
a quotation from the f ir s t  President* s address to the reconstituted 
Glasgow Medico-Chirurgical Society in 1815* That he should have 
chosen the subject o f  erysipelas for  his Presidential Address indicates 
the seriousness with which the disease was regarded at that time.
Indeed, a le t te r  appeared in the Glasgow Herald o f  Monday 14th February, 
1814, drawing attention to the danger associated with i t s  occurrence 
in the over-crowded wards o f  the Royal Infirmary'55’ ) • The proof that 
an e ffective  method o f  treatment had been found for  erysipelas, therefore, 
was o f  le ss  importance than the fact that the tr ia ls  o f  the new drugs 
in this disease formed a basis fo r  further experiments in many other 
in fections o f greater severity.
For myself, the evaluation o f  one o f  the drugs in the treatment 
o f  pneumonia was an important culmination. For, during a period o f 
fifteen  years a great part o f  my c lin ica l work has been concerned with 
the management o f  cases o f adult pneumonia. No one need emphasise 
the importance o f this disease as a serious cause o f  mortality.
Our babkground o f knowledge o f  the "untouched" pneumonia i s  very 
fu l l .  My own early study  ^of. the disease had confirmed the importance 
o f  the pneumococcus as the e tio log ica l agent, end, during 193^-3^
I isolated , and typed serologica lly , the causative pneumococcus from 
a considerable number o f  cases. Now the selection o f  cases for 
admission to the Glasgow Fever Hospitals was dependent upon n otifica tion  
by the general practitioners o f  "Acute Primary Pneumonia". I t  was 
generally assumed that this term comprised those in fections which /
-56- *
"It  then attacked with undescribable violence various patients in
different parts o f  the house. Three persons.............were speedily
k ille d  by i t ; .................while in a third o f  those affected by i t ,  the
poison spared l i f e ,  but induced a lingering and painful disease."
(ii)
(iii)
which broadly conformed in the adult to the usual text>-book description 
o f  lobar pneumonia. I t  was, however, ray early experience that a 
clear-cut bedside c la ss ifica tion  into the two pathological forms, 
lobar end lobular, was often not easy. Indeed, even among those 
cases with a -common etio log ica l agent, one oftem met examples where 
the consolidation’ was not o f  a s tr ic t ly  lobar distribution, nor were 
the other characteristics typical o f  th is usually well-defined entity. 
Such was especially true as one entered the older age groups, 
particularly over forty  to fo r ty -fiv e  years o f  age; here, even type I 
or type II pneumococci, which most frequently produced a lobar form 
o f  consolidation, were often iso la ted  from cases which conformed 
c lin ica lly  more to the lobular description.
The climate o f  the West o f  Scotland, end the concentration o f 
heavy industries therein, were, o f  course, often responsible for  a 
chronic pulmonary catarrh which affected many o f  the patients.
Indeed, i t  was very common in those past middle l i f e  to obtain a 
history o f ’’chronic chest trouble”. I t  would be reasonable to argue 
that this precedent bronchitis might tend to predispose the subject 
to assume a bronchial rather than a parenchymatous reaction.
But such an argument merely serves to emphasise that, no matter
what the stimulus, i t  i s  the host who ultimately decides the manner
o f  his tissues’ reaction. Looked at in this way, the distinction
between the two forms o f consolidation l i e s  more in the capacity which
the host can display to withstand the in fectiou s agent. The greater
severity o f bronchopneumonia i s  thus explained, not so much by any
properties o f  the disease-process i t s e l f ,  as by the in a b ility  on the 
part o f  the person attacked to raise an e ffectiv e  resistance to the 
attacking micro-organism.
Such an explanation i s  in  keeping with the greater frequency 
o f  bronchopneumonia at the extremes o f  l i f e .  Man at his prime, i t  
would seem, can summon up a fa ir ly  active resistance to pneumococcal 
in fection : a resistance which engenders a response o f  a lobar type.
In this respect i t  seems an important c lin ica l observation that the 
most classical lobar consolidations are to be found between the ages 
o f  fifteen  and twenty-five years. In the very young and the very old 
the pneumonia administers the fin a l and obvious blow to a resistance 
already enfeebled — in the young perhaps by malnutrition — in the 
old by the degenerative processes which are part o f  advancing age.
Such a point o f  view is ,  o f  course, familiar: but i t s  restatement
i s  perhaps timely. There i s  a real danger in regarding disease as 
an entity. I t  i s  well that we should remind oui*selves that in fectious 
disease, particularly, i s  a summation both o f  the .defences o f  the 
host as well as the attacking mechanism o f  the pathogen.
I
I t  may be suggested that the same train o f  thought can be followed 
in considering the method o f treatment. There can be l i t t l e  doubt that 
the term chemotherapy, as generally accepted, suggests the application 
to an acute in fection  o f a chemical - substance which has two attributes. 
I t  must show a high degree o f  harmful e ffe c t  to the in fecting 
pathogen, while at the same time showing an absence, or at least a 
minimal amount, o f  harm to the c e lls  o f  the host. A chemotherapeutic 
agent is ,  as i t  were, something which maims or k i l l s  the parasite 
without k illin g  the host. This raises in the mind a picture o f  a 
foim o f  treatment which leaves l i t t l e  to the host to accomplish.
Indeed, such an attitude has been encouraged, in the case o f  the /
(v)
the sulphonamides, by the discovery that they display a defin ite
/
bacteriostatic e ffe c t  in v itro . I t  would be fa ir ly  true to say 
that, with the exception o f  the purely c lin ica l .reports, the great 
bulk o f the published work upon the action o f sulphonamides has 
dwelt upon this aspect o f  the problem — the antagonism o f  chemical 
and bacterium. Treatment, i t  would seem, is  a matter o f  securing 
an adequate concentration o f  a particular drug in order to attack 
e ffectiv e ly -a  particular pathogen. The host becomes a mere passive 
agent whose only function is  to arrange fo r  the removal o f  the 
dead or dying organism. •
I t  seems to me that this view i s  essentially unsound.
Surely chemotherapy supplies the host with a material which supports 
his own attack upon the pathogen. When chemotherapy fa ils  o f  i t s  
purpose, namely, the cure o f the in fection , search fo r  the cause 
o f  the fa ilu re must ihclude a study o f  the reaction which the 
in fection  should have set up in the host. In other words, chemical 
plus a resistant host implies success; chemical plus a non-resistant 
host implies fa ilu re. Such a conception requires emphasis i f  the 
future study o f  these methods o f  treatment is  to be properly focussed; 
fo r  i t  places the burden primarily upon the person in fected . I t  
demands for  the further improvement o f  treatment a more precise 
knowledge o f  the factors which go to make an e ffe ctiv e ly  resistant 
ho st.
These arguments may be summed up thus: on the one hand, the
form o f  an acute in fection  i s  the resultant o f  two forces — an 
invading pathogen and a varyingly resistant host: and, on the other,
that successful chemotherapy depends upon f ir s t ,  the use o f an /
an active chemical; second, the*presence o f  a pathogen susceptible 
to i t s  action; and third, a host whose defences against in fection  are 
in a healthy state. By over-amp ha sis o f  the part played by the 
chamical or the pathogen there i s  a tendency to overlook the important 
fa ctor 'common to both disease and treatment, namely, the condition 
o f  the host.
I t  might fin a lly  be advanced that the condition o f  the host and 
his reaction to the acute in fection  must be borne in mind in yet 
another direction — the very conduct o f  the tr ia ls  themselves. I t  
i s  not always su ffic ien tly  appreciated that the e ff ic ie n t  evaluation 
o f  a method o f treatment demands careful planning, which must take 
into account both the method o f  treatment to be used and the vagaries 
o f  the disease to be treated. In the present thesis, two systems o f  
c lin ica l tr ia l are portrayed.
f
When the original tr ia l o f  sulphonamido-chrysoidin was 
contemplated, the natural behaviour o f erysipelas was reviewed.
In the f ir s t  place, i t  was clearly a disease in which the mortality 
was not high; and, moreover, death was due often not so much to the 
disease i t s e l f  as to eome degenerative process previously present.
One great advantage, however, which this disease possessed for study 
was that there wras a continuous flow o f c lin ica l material, o f  which 
the average in-patient duration o f stay was not long. Such an
in fection  presented an unanswerable argument for  the planning o f  'a
tr ia l in which each alternate case received the method o f treatment
under tr ia l. The value o f such a method was further enhanced by
choosing certain measurable factors o f  assessment o f  c lin ica l cure 
and comparing, in the two groups o f cases, the duration o f .each. Y»ith /
(vi)
(vii)
Yvith such an experimental method, i t  might be assumed that each 
group o f  cases, when su ffic ien tly  large, would contain similar 
proportions o f a ll the d ifferent c lin ica l forms o f  the disease,
This is  undoubtedly the ideal method. But, when a tr ia l o f 
a new drug in pneumonia was decided upon i t  was at once clear that 
this disease demanded a d ifferent form o f assay. To begin with 
pneumonia carried a high mortality; and, moreover, a preliminary 
tr ia l o f  a sulphonamide drug had already been reported in the 
medical literature , which suggested that i t  induced a favourable 
response in this disease. Clearly, with an e ffective  method o f 
treatment a stage would very quickly be reached when the clin ician 
would be confronted with the problem — i t  had arisen even in the 
treatment o f erysipelas — whether the drug could ethically be 
withheld from severe cases, further, the duration o f  stay in 
hospital o f  the case o f pneumonia was longer, so that the turnover 
o f  patients was much slower. Yihen to these considerations was added 
the fa ct that their care would demand not only more detailed c lin ica l 
supervision but a considerable amount o f bacteriological work, i t  was 
clear that the alternate case system o f control was not the 
practical one fo r  the individual investigator. I t  was accordingly 
decided to adopt the plan o f  treating a consecutive series o f 
patients in an exactly similar fashion; o f  conducting in a ll o f
them a similar method o f c lin ica l and bacteriological examination so 
that the behaviour o f the in fection  could be assessed; and o f 
observing in a ll o f  them the e ffe ct  o f  the treatment upon certain
chosen characteristics. Such a method demanded f ir s t  that t h e r e  s h o u l d  
be a suitable series o f cases from past experience which could serve /
(viii)
serve as a rough yardstick against which to measure the effect of the 
drugs; and second, that all efforts should be concentrated on attacking, 
in the most careful fashion, the validity of the resillts. As regards 
the first, i t  was hoped that the earlier experience with the disease 
would prove of great value; and, as regards the second, i t  resulted 
in an interest in statistical methods which I have endeavoured to 
apply to all of the findings.
Facilities for the observation of the clinical material were 
obtained in Ru chill Fever Hospital through the courtesy of Dr* W*M. 
Elliott. To many members of the hospital staff I am indebted for 
their valuable assistance. In particular I would record my thanks 
to Sisters B. Duncan, A.A. Giant, M. McPhail and M. McFlggins who 
were in charge of the nursing management of the erysipelas and 
pneumonia wards. Mr. Thomas B. Gallie, senior technician in 
the hospital laboratory, was my constant assistant over msny years 
end I am happy to acknowledge his unstinted help.
To Dr. John M. Cowan and Dr. Robert Cruickshank I owe much for 
their advice and continued encouragement. It was they who first  
stimulated my interest in the problem of pneumonia; any merit which 
rests in the second part of the investigation is  in large measure
due to the sound foundation which they helped me to lay in the 
earlier study of the disease begun in 193
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CLINICAL STUDIES IN SULPHDN AMIDE CHEMOTHERAPY.
V^ !UML  h .
ERYSIPELAS.
^Respecting the nature and treatment of a disease which has been 
so long known and of such frequent occurrence, one would naturally 
have thought that the minds of medical men would have been completely 
made up. This, however, is  by no means the case; on the contrary, 
there are few subjects in medicine where a greater diversity of 
sentiment prevails. ”
Observations on the Nature and Treatment of Erysipelas”
From the First Presidential Address to the Glasgow Medical Society by 
Robert Watt, M.D. January 17th, 1815*
S U M M A R Y .
VOLUME I .
CD
VOLUME I The Chemotherapy of Erysipelas.
Chapter I : Introductory. pp. 1 - 8.
The work is  introduced by selecting for review some of the more 
important experimental findings obtained with the sulphonamide drugs 
which are thought to form a basis for their clinical application.
ChEpter II : A Study of the Natural Behaviour of Erysipelas, pp. 9-25*
A series of 6,626 cases of erysipelas admitted to the wards of 
Buchill Fever Hospital is  studied with relation to the following 
characteristics:-
1. Annual variations in Incidence and Severity (p. 11).
2. Seasonal variations in Incidence and Severity (p. 13)*
3. The Sex and Age Constitution (p. -16) ♦
4. Variations in Severity with Sex and Age (p. 21).
In some sections the survey is  amplified by a consideration of the 
notifications and deaths reported for the City of Glasgow as a whole and 
for Jhgland and Wales. I t  is  shown that the natural behaviour of erysip­
elas is  such as to demand great care in the planning of a therapeutic 
experiment. In chief, i t  is  decided that two particular errors must 
be avoided. First, any attempt to choose certain cases on the grounds 
of severity will be dangerous; and second, the fatality rate of a 
series of cases must be used with caution as a factor of assessment.
Chapter III : The Choice and Definition of the Factors of
Assessment. pp. 26-33.
(ii)
1. The duration, in days, of spread of the local lesion.
2. The duration, in days, of primary pyrexia.
3. The duration, in days, of primary toxaemia.
4. The incidence of complications.
5. The fatality rate obtained.
6. The incidence of relapse.
7* The duration, in days, of residence in hospital.
The first three of these are regarded as the main criteria of 
assessment. A special case-sheet for use with each patient was 
drawn ups and a "punch-card" was made out for each case.
Specimens of these are shown.
Chapter IV s The Plan of the Experiment. pp. 3L-39*
The method of administration of the different forms of treatment 
used is  defined. Details are supplied of the procedure adopted for 
allocating cases to these different forms of treatment: the actual
numbers dealt with and their subdivision into various groups are 
described.
Chapter V : Analysis of the Besults of Treatment. pp. 40-104.
This chapter is  divided into five parts.
Part 1. (pp. 41-62). The question is  asked, "Is chemotherapy 
effective?" A series of 618 cases is  reviewed and the findings are 
summarised in Table a copy of which is  appended. The table leaves 
no doubt that those who were given a sulphonamide drug recovered more 
rapidly and more completely than did those who received the control 
method of treatment.
TABLE 15.
Summary of Results.
Comparison of Chemotherapy and Ultra-Violet Light.
( i i i )
Factor of Assessment.
Chemo­
therapy 
(per cent.).
Ultra-violet 
Light, 
(per cent.).
Difference
(S.E.D.)
1. Ceased spread after 
24 hours in hospital. 90.1 54 10.9
2. Apyrexlal after 48 
hours in hospital. 81.7 49.4 9.0
3* Toxaemia absent after 
72 hours in hospital. 80.7 55.4 7.0
4. Complicated Case Rate
(true infective com­
plications). 11.6 I8 .3 2.4
5* Nephritis, - 2.6 2.9
6. Relapse Rate. 3-2 6.9 2.1
7. Fatality Rate. 2.9 3-3 -
8 . Average Days Residence 15.34 17.16 -
Total number of cases 312 3)6
(In the last column is  shown for each factor of assessment the ratio of 
the percentage difference to the Standard Error of the Difference (S.E.D.))
Part 2. (pp. 63- 69)* In this section the results obtained with 
chemotherapy in a group of one hundred children under the age of 
five years are supplied. At this age, erysipelas in the past usually 
ran a severe course. I t  is  found that, in respect of the spread of 
the lesion and the duration of fever and toxaemia, the results differ 
l i t t le  from those reported in Part 1. The incidence of complications, 
however, in this age group is  high.
Part “5. (pp. 7D-75)* 4 series of patients who were admitted on
their first day of illness is  now studied. The cessation of spread in 
this group.is slightly delayed when compared with the larger group 
analysed in Part 1: but i t  is  suggested that such a result might be
expected since a group of patients admitted so early would show a 
high proportion of active and acute lesions.
Part 4. (pp. 76-81)* Reference is  now made to the results obtained 
in an unselected group of cases which received no specific form of 
treatment. I t  is  shown that in one-third of this group spread ceased 
after admission to hospital. This figure serves to focus the results 
obtained with sulphonamides more sharply: and shows that the control 
method of treatment (irradiation with ultra-violet light) was of 
some beneficial effect.
Part 5* (pp. 82-104). The chapter is  concluded by examining the
consistence of the results during the three and a half years of the
experiment: by studying the effect of the introduction of the
sulphonamides upon the mortality from the disease in Glasgow and in
Eh gland and Wales: and by recording and analysing the individual 
deaths which occurred among the sulphonamid&-treated cases. The /
(v)
The results accumulate to show that the drugs have completely altered 
the behaviour of the disease. Indeed, I t  Is submitted that a failure 
of treatment could only be ascribed in two cases, both infants.
Chapter VI : A Study of the Effect of Different. Scales
of Dosage. pp. 105-116).
An interesting experiment is  related in which groups of cases 
received different scales of dosage. I t  is  found that an increase in 
the daily amount of drug given increases the rapidity with which 
spread ceases. A stage is  reached, however, beyond which the 
improvement obtained does not parallel the rise in the dose of drug. 
Further, as the dose of drug is  enlarged, there Is a tendency for 
pyrexia and toxaemia to be prolonged. As a result of the experiment 
i t  is  advanced that the optimal dose of sulphanilamide for cases 
of erysipelas is  in the region of six grammes daily.
Chapter VII : Discussion. pp. 117-123*
I t  is  pointed out that the drugs are most effective in limiting 
the spread of the local lesion. Attention is  drawn to the disappointing 
reduction of those complications of a pyogenic nature: for even in 
patients who received treatment from the first day of their illness 
complications of this kind occurred in about twelve per cent. I t  is  
suggested that these results support a belief that the drugs antagonise 
or neutralise a characteristic of the streptococcus which may be 
termed invasiveness.
VOLUME I.
CHAPTER I.
INTRODUCTORY.
-  1 -
In I 935, Domagk reported the investigations which had culminated 
in his development o f  2.4-diamino-azc-benzene-4-sulphonamide 
hydrochloride (sulphonamido-chrysoidine), patented as Prontosil Red.
This discovery opened up new fie ld s  in the therapeutics o f  acute infections? 
fie ld s  from which the f i r s t  fru its  in d in ic e l  medicine are s t i l l  
ju st being garnered.
In the rush o f the development o f  "newer and better" compounds, 
i t  i s  sometimes forgotten that the clin ician  must needs be slow in his 
provings o f  new drugs. The co llection  o f adequate numbers fo r  careful 
analysis is  a slow process: and there is  a natural tendency for  him to 
be hurried on to the la test achievement o f  the laboratory almost before 
the la s t  has been properly tested upon man. There is ,  therefore, some 
value in returning to some o f  the earlier c lin ica l work in the hope that 
by reassessing i t  we may place our knowledge upon a surer foundation.
During the period 1^6-1^40  I conducted a series o f  c lin ica l therapeutic 
experiments relating to the e ffe c t  o f  the sulphanilyl group o f  drugs 
upon several o f  the acute coccal in fections. My results in two o f 
these, erysipelas and pneumonia, w ill be studied in the following pages.
To attempt to survey the literature regarding the sulphonamide 
drags would, at this time, seem to me unwise and, in this place, 
unncessary. Unwise, because our present knowledge i s  too scanty for  
the formation o f  sound opinions: unnecessary because my purpose is
purely that ofi a c lin ica l investigator. The results which I have 
obtained vith the drugs in therapeutic tr ia ls  must stand upon their own 
foundation. They are themselves o f  su ffic ien t extent to require as fu ll 
an examination as I am able to give them.
No clin ician , however, can afford to set aside the results o f  
experimental laboratory work. I f  his therapeutics are to rest upon a 
rational basis he must constantly s i f t  and examine such results in an 
endeavour to understand their c lin ica l application. In introducing a 
discussion upon the results obtained with the sulphonamide group o f 
drugs in erysipelas and pneumonia, i t  i s  therefore appropriate to begin 
by making a selection o f  those experimental findings which have seemed 
to me to bear most intimately upon their c lin ica l use.
The action o f  the original, dye sulphonsmido-chrysoidine at once 
presented a striking anomaly; for  although i t s  value as an anti­
bacterial agent a fter absorption by the host seemed undoubted, i t  was 
found to have no bacteriostatic e ffe ct  in v itro . British end French 
workers developed this problem along d ifferent lin es . In France the 
Trefouels, N itti and Bovet (1935) t carried out experiments vath the 
red dye, sp litting i t  at the azo linkage. They showed that while many 
active compounds could be produced so long as the sulphonamide nucleus 
was retained, compounds formed from the other radicle  were usually 
inactive. They also demonstrated that the radicle  p-amino-benzene- 
sulphonamide was as e ffe ctiv e  as the original red dye in controlling 
streptococcal in fections in the mouse. As a resu lt o f  these experiments 
two particular compounds were elaborated for  which c lin ica l e ffic ien cy  
was claimed. The f i r s t  o f  these, 6. carboxy-2 :4-diamino-4* sulphamido- 
azobenzene, (Ry.biazol), was fa ir ly  obviously an attempt to copy the 
original sulphonamido-chrysoidine as closely  as possible. The second, 
p-benzyl-amino-benzene-sulphonamide was one o f  the substances prepared 
from the sulphonamide radicle . Both o f  these compounds i t  was claimed
-  2 -
- 3 -
claimed gave r ise  to fewer tox ic side e ffe cts .
In Britain, Colebrook, Battle and 0*Meara (193^) showed that although 
sulphonamido — chrysoidine was inactive in v itro , the blood o f  patients who 
received i t  was bactericidal for  streptococci: and Fuller (1937) reported
that the blood o f individuals to whom sulp hon ami do- chiy so i  din e was 
administered, contained p-amino-benzene-sulphonamide. This la tte r  
substance was i t s e l f ,  as has been said, bacteriostatic in v itro ; a finding 
which had two important results. On the one hand, i t  tended to enlarge 
the range o f  c lin ica l research, fo r  supplies o f  this drug were not only- 
more easily obtained, b it  were cheeper since i t  was free  from patent.
On the other hand, i t  tended to stress the importance o f the radicle ; for 
as further drugs were elaborated and found to suffer the same breakdown 
to sulphanilamide i t  looked as i f ,  in th is la tte r  drug, a fina l stage 
o f  discovery had been reached. Where a ll drugs must f i r s t  be s p lit  to 
produce a radicle which was i t s e l f  known to have bacte iiostatic  power, i t  
seemed most lo g ica l to administer that radicle. I t  was not lin til the 
synthesis o f  2-  sulphanilyl- amino-pyridine (sulphapyridine) was reported 
that this chain o f  reasoning was broken. For f i r s t  Whitby (1938)* 
experimentally, and then Evans and Gaisford (1938)? c lin ica lly , brought 
forward evidence which suggested that this new compound possessed a 
wider range o f  effectiveness than either the original sulp hon ami do- 
chrysoidine or the la ter  sulphanilamide. Although Domagk in his original 
report had sp ec ifica lly  stated that sulphonamido-chrysoidine was 
in e ffectiv e  in pneumococcal in fections, some workers had suggested that 
sulphanilamide possessed slight antipneumococcal power (Cooper, Gross
and Lewis, 1938)* There seemed l i t t l e  doubt, however, that the new 
drug, sulphapyridine, showed powerful activ ity  against this micro-organism:
/
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micro-organism: and i t s  action apparently was not due to any breakdown
in the body — at least with the formation o f  sulphanilamide. Since 
that time a series o f compounds o f  similar structure has been discovered: 
and, although fresh claims are made as each arrives, i t  i s  clear that 
from one point o f view they sre but "variations” on the earlier drug — 
sulphapyridine.
The most important contributions to the study o f  the absorption 
and excretion o f  the drugs were made, principally using sulphanilamide, 
by Marshall, Emerson and Cutting (1937)* These workers showed that, 
although individual variations occurred, the absorption from the 
in testinal canal was good. My own previous experience (fo r  example, with 
antitoxins) in the treatment o f  acute in fection s had been that intravenous 
therapy obtained improved results. In some o f  my early cases o f 
erysipelas, in fa ct, I had had no hesitation in administering the 
drugs parenterally; to find to my surprise that no added benefit could 
be observed. I t  was soon made manifest that oral therapy was lik e ly  
to be more beneficia l, for  Marshall and his co-workers showed not only 
that the drugs were T/ell absorbed from the bowel txit that they were 
mainly excreted by the kidney; and that i t  was possible, when the drug 
was given by mouth, to strike a balance between absorption and 
excretion wrhich permitted the concentrations o f  the drugs in the blood 
stream to remain relatively  constant.
These workers, too, showed that in certain animals, including 
man, part o f  the ingested drug became conjugated in the liv e r  so that 
the drugs appeared in the blood and urine in  two forms — an unaltered,
free portion and a conjugated or acetylated portion. Long and ELiss 
(1939) la ter  reported that the la tte r  portion had no e ffe ctiv e  /
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e ffe ct iv e  antibacterial action. They suggested that the proportion o f  
drug which was acetylated increased as i t s  administration was prolonged.
I t  thus seemed that the longer treatment was continued, the more drug 
became inactive. Perhaps o f  more importance c lin ica lly  was the discovery 
that while the so lu bility  o f  the sulphonamides was poor, the acetylated 
portion was even less  soluble than the original drug. Where the kidneys 
played such a large part in their excretion, i t  became clear that the
t
flu id  intake and output o f  patients receiving a sulphonamide was a 
matter o f  importance.
The present chapter may be concluded by referring to the most recent 
work regarding the possible action o f  the drugs. Woods (1940) was the 
f i r s t  to draw attention to the relationship between sulphanilamide and 
jo-amino-benzoic acid. He suggested that the inhibitory e ffe c t  o f  jo-amino- 
benzene-sulphonamide on bacterial growth might be due to interference 
with the functions o f £ -amino-ben zoic acid ( and structurally similar 
groupings) in regard to the bacterial ce ll . Fildes (1940) in a masterly 
exposition o f  the new conception showed that £ - amino-ben zoic acid was 
an "essential metabolite" fo r  bacterial growth. Rubbo and G illespie 
(1940 and 1942) reported that, fo r  a particular organism under study, the 
acid was an "essential growth factor", and that i t s  activ ity  in this 
respect was overcome by the addition o f  sulphonamides; not o f  
sulphanilamide alone but also o f  sulphapyridine. Titration experiments 
suggested that to overcome one part o f  £-amino-benzoic acid, about
26,000 parts o f  £-amino-benzene-sulphonamide were necessary. They further 
adduced that there was a chemical parallelism between the growth factor
and the chemotherapeutic agent and suggested that the structural 
configuration o f  a chemotherapeutic agent must conform to the structural /
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structural pattern o f  an essential growth factor for  the organism.
Strauss, Lowell and Finland (1941) suggested that there was a roughly 
lin ear relationship "between the concentration o f a sulphonamide which 
with a minimal concentration o f  jd-  amino- ben zoic acid, would in h ib it 
growth. Their experiments tended to show that in the neutralisation o f 
the benzoic acid, sulphathiazole was more e ffective  than sulphapyridine 
and both than sulphanilamide.
Much o f  th is work has been confirmed, and there now eeems l i t t l e  
doubt that in vitro the antibacterial action o f  the sulphonamides i s  
dependent upon i t s  capacity to in terfere between the bacterial ce ll  and 
some chemical substance closely related to the sulphonamide structure, 
which i s  essential fo r  the growth and m ultiplication o f  the c e ll. Such 
an interpretation o f  the action o f the sulphonamides suggests one 
conclusion which must be o f major importances namely, that even when the 
drugs have performed their function* i t  w ill s t i l l  be necessary for  the 
host fin a lly  to overcome the in fecting organism.
Now our present conception o f  the therapeutics o f  acute in fectious 
diseases has been founded upon what might be termed a basis o f  sp ec ific ity . 
In e ffe c t  we have argued that the f i r s t  necessity i s  to find the sp ecific  
e tio log ica l agent o f  the disease. This necessity satisfied , i t  was 
essential to find out how that agent achieved i t s  harmful e ffe ct . Rational 
therapy then depended upon the production o f  a sp ecific  anti-substance
which, supplied to the host o f  the in fection , would enable him to neutralise/
the harmful substance or e ffe ct . Such a viewpoint upon therapeutics has
tended to emphasise the sp ec ific ity  o f  cause and to direct attention away
from that other facet o f  any acute in fection , namely the ’’constitution" o f  
the host attacked; although, clearly, his natural defences against invasion 
must be o f  prime importance in his recovery.
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Just because the sulphonamides are antibacterial agents this 
emphasis upon sp ec ific ity  tends to be continued and attention concentrated 
upon the bacterial end o f  the in fection ; forgetting that one o f  the most 
surprising features o f  the drugs i s  their very breadth o f  activ ity . 
Sulphanilamide appears to be equally e ffe ctiv e  in in fections due to 
streptococci, gonococci, and meningococci; sulphapyridine seems impartial 
whether the etio log ica l agent is  pneumococcal, streptococcal or 
meningococcal. I t  i s  true that this lack o f  sp ec ific ity  i s  not complete; 
for e l l  micro-organisms are not equally susceptible to their action.
But i t  i s  true that within a fa ir ly  wide range, the sulphonamides supply 
a key to the more e ffic ie n t  management o f  many acute in fections o f  
diverse etiology. This might suggest that the action o f  sulphonamides 
depends upon the non-specific resistant powers o f the host rather than 
that i t  assists his sp ecific  immunological response. Such a lin e  o f  
reasoning vdll be developed further when the results o f  the present 
investigations are discussed.
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CHAPTER II.
A Study o f  the Natural Behaviour o f  Erysipelas.
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Before attempting to assess the value o f  a new method o f  treatment 
in any acute in fectious disease, a knowledge o f  i t s  natural behaviour is  
essential. Such knowledge w ill indicate what factors are lik e ly  to a ffect 
the course o f the disease, quite apart from the treatment applied, snd w ill 
probably indicate what are the best cr iter ia  to use in measuring the 
success or fa ilu re  o f  the new therapy. In the present chapter, therefore,
I propose to discuss certain features o f  the epidemiology and natural 
behaviour o f  erysipelas which emerge from the study o f  a series o f  6,626 
cases o f  erysipelas admitted to Ru ch ill Fever Hospital during the years 
X928-1933* Over practica lly  the whole o f  this eleven year period I was 
in charge o f  the erysipelas wards in this hospital, so that a large 
proportion o f  the cases came under my personal care.
Many Local Authorities make l i t t l e  provision for  the treatment o f  
erysipelas in the wards o f  their Fever Hospitals. The Public Health 
Department o f  the City o f  Glasgow, however, has at a ll times set aside 
accommodation for the disease. The la te  Dr. J.B. Russell, at that time 
Medical O fficer o f Health to the City, stated in 1895 n^ Te have always been 
in the habit o f  treating cases o f erysipelas in hospital for  humanitarian 
reasons” : although la te r  in  the same report he complained o f  the increased
admissions to hospital resulting from the introduction o f the N otification  
Act, saying ”Ample as the resources o f  Glasgow are, erysipelas is ,  as 
regards hospital treatment, a great nuisance." Despite this complaint, 
however, the hospitalisation o f  a large proportion o f  the cases occurring 
in the City has continued up to the present time. About the year 1925* 
in order to conserve accommodation, i t  was decided to concentrate a ll the /
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the Glasgow cases in one o f  the City Fever Hospitals (Ruchill Fever 
Hospital) and accordingly large male and female wards were set aside 
for  the purpose. Table 1 shows that a high proportion o f  a ll registered 
cases has been admitted to the hospital annually. (One advantage o f  
using mainly hospital cases fo r  the purpose o f  this review i s  that 
the diagnosis has been confirmed. Table 2 shows that in a moderate 
proportion o f  cases (average 13*5 Per cent.) the diagnosis o f 
erysipelas i s  not confirmed after admission to hospital. Such 
errors in diagnosis remain unchanged when the patient is  treated 
at home).
TABLE I .
Proportion {%) o f  Registered Cases o f  Erysipelas in the City o f 
Glasgow admitted to Hospital (1928-1938)*
lear
Number o f
Registered
Cases.
Percentage 
admitted to 
Hospital.
1923 922 51.4
29 1,098 53-5
30 1,259 51.2
33- 1,097 49.9
32 1,045 51-5
33 1,117 59.3
34 1,111 57.3
33 1,014 65.2
3^ 977 65.9
37 1,038 64.2
38 969 62.3
TABLE 2.
Rate o f  nAltered Diagnosis" in Cases admitted to Hospital 
as Erysipelas (1937-1939)•
Tear Admissions Diagno sis Confirmed.
Diagnosis
Altered.
"Altered 
Diagno sis" 
Rate %•
1937 579 472 102 1 7.6
1938 701 608 93 1 3.2
1939 757 670 87 11.5
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These are, therefore, three good reasons for  regarding the 6,626 
cases o f erysipelas as'an adequate sample o f  the disease; f ir s t ,  because 
a high proportion o f  a ll  registered cases i s  admitted to hospital; 
second, because one hospital receives cases from a ll areas o f  the City; 
and third, because the diagnosis o f  erysipelas has been confirmed.
Although these hospitalised cases w ill form the main basis o f  the analysis, 
where i t  i s  thought that a comparison may be valuable i t  i s  intended also 
to use the figures for  n otified  cases for  the City as a whole, or for  the 
whole country.
1. Annual Variations in Incidence and Severity.
A reference to Table 3  shows that there i s  a slight annual variation 
in the number o f  cases admitted. During the eleven years the annual 
admissions averaged 602 with a maximum in 1937 o f  670 and a minimum in 
I 929 o f  485* A broader picture o f  the incidence o f the disease over a
more prolonged period i s  obtained by abstracting the case-rates per 
m illion o f  the population, from the Annual Reports o f  the Medical O fficer 
o f  Health o f the City o f  Glasgow, for  the years I 9I I - I 939 inclusive (Fig. 1 ). 
Although the period opens with a high incidence o f the disease, after 
I 9I 6 the figures remain fa ir ly  steady between upper and lower lim its o f  
1,15 6  in 1930 644 in 1918. I t  i s  obvious that the in fection  is
constantly prevalent, although at no time does i t  show an unusually 
high rate.
MILL IOW
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TABLE 5 .
Erysipelas,
Annual Admissions to Hospital,
1923 -  19337
Tear Male
Cases
Female
Cases Totals
1923 233 252 485
29 281 296 577
^0 306 330 636
31 242 280 522
32 249 284
33 3L4 342 656
34 3^7 31-5 632
35 332 33D 662
36 316 329 645
37 350 320 670
3 300 308 608
Totals 3, 240 3,386 6.626
Annual variations in the severity o f  the disease as expressed by- 
death rates are also, perhaps, best studied by using larger figures than 
can be obtained from hospital admissions. For, since those cases which 
enter the hospital may comprise the more severe forms o f  the disease, the 
m ortality among them may not give a true picture. To avoid this error,
I have compiled two sets o f  figures, namely, the mortality rates per 
1,000 registered cases fo r  Glasgow (1911-1939) and fo r  England and Wales 
( I 9I I - I 938) .  These rates are shown in Figure 2.
The Glasgow figures show considerable variation. In general, however, 
the rate is  above 40 with a peak in 1921 o f  66. The graph i s  rather 
irregular and exhibits no defin ite trend except in the la st  four years,
during which the mortality rate has dropped sharply. The figures for  
England and Wales, on the other hand, show a gradual rise  in the rate up 
to and including 193 >^ while even in 1935 193  ^ "the rates are well /
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well above those obtaining during the previous 20 years. There is  no 
obvious parallelism between the two graphs but neither gives evidence to 
suggest any diminution in the mortality o f  the disease, except in the la st 
3-4 years, (The fa l l  in mortality which has occurred since 193& v.ill be 
the subject o f  discussion la ter but i t  may be noted in passing that 
chemotherapy was introduced' in.Glasgow during 193  ^ in the country 
generally in or about 1937) •
Both graphs clearly demonstrate some cyclica l fluctuation in mortality, 
although the rate is  by no means high, l/Vhen i t  i s  remembered, however, 
that some 15,000 cases are n otified  in England and Wales annually, i t  can 
be realised that erysipelas i s  responsible for  a considerable number 
o f  deaths.
2. Seasonal Variations in Incidence and Severity.
Previous writers have referred to variations in the incidence o f the 
disease at d ifferent periods o f  the year. Ker (1Q2Q) commented on the 
increased number o f  relapses noted during periods o f  cold weather and 
assumed that such conditions favoured the original attack. Riddell (1935) 
reviewing figures for  Stirlingshire showed that the maximal incidence 
occurred in the la s t  quarter o f  the year, and Rolleston and Ronaldson (1940) 
affirmed this as their own experience. My own figures are shown in 
Figure 3 . The fourth quarter o f the year has supplied the greatest 
number o f  cases in a ll but three years, namely 1929* 1932 and 193 *^
Almost more striking i s  the low incidence in the third quarter o f  the 
year, to which there i s  but one exception, (I 930) ,  when the second quarter 
yielded a sligh tly  lower figure. There is  then marked seasonal variation
in the incidence o f  the disease which is  lowest in the period July- 
September and highest in the period October-December.
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TABLE 4.
Quarterly Admissions o f  Erysipelas
6,626 Cases : 1928-1938*
Quarter Male
Cases.
Female
Cases.
Total
Cases.
Proportion (per 
cent.) both sexes 
and Standard Error.
1 st 864 902 1,766 26.6 + 1.05
2nd 7 66 822 1,588 24.1 ± 1.07
3rd 629 648 1,277 19-2 ± 1 .1
4th 981 1,014 1,995 32*2 ±  1 .0 3
Totals 3,240 3,386 6.626 100.0
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The figures sre summarised in Table 4 when i t  i s  apparent that the 
.seasonal variation i s  true for both sexes. Applying the standard error 
o f  difference as a test o f  significance, we find that —
(i)  The difference between the 1st and 2nd quarters i s  not 
sign ificant.
( i i )  The difference between the 2nd and 3rd and the 1st and 3rd 
quarters i s  more than three times i t s  standard error and is  
therefore significant.
( i i i )  The difference between the 3rd and 4th quarters i s  about
seven times i t s  standard error and is  therefore sign ificant.
(iv ) The difference between the 2nd snd 4th quarters i s  almost
four times i t s  standard error and is  significant.
(v) The difference between the 1st and 4th quarters i s  twice i t s
standard error and is  therefore barely significant.
The statement is  frequently made that erysipelas is  more fa ta l in cold 
weather but there are few figures from large series o f cases to support 
the statement. The most valuable figures in this respect are those o f 
Lewis Faning (1940). Faning calculated for erysipelas the Standardised 
Death Rate per day in each month per m illion o f  the population for  England 
and Wales end in Figure 4 these rates are compared with the monthly fa ta lity  
rates per cent, for  the 6.626 cases in my own series. There is  an obvious 
sim ilarity between the two curves and they show that the winter mortality 
i s  much greater than the summery in fact the rates for January, February, 
March end April are fu lly  double those prevailing in July, August and 
September, an observation o f considerable importance in assessing the 
value o f a method o f  treatment.
VARIATION INSEASONAL
RUC.H ILL
3* The Sexand Age Constitution ,
Of the total 6,626 cases there were 3> 240 males (48.7 Per cent.) and 
3,386 females (51*3 Per cen t.). This apparently higher incidence in 
women is  an interesting feature. Ker (1909)* in an analysis o f  800 cases, 
states that there were 43*5 Per cent, males and 5^*5 Per cent, females.
In R id d e lls  (1935) Scottish series 59*3 Per cent, o f  the cases were
o
women. Brandberg and Akeson (1937) give the sex incidence in 298 
Scandinavian cases as — males 41.2 per cent, end females 58*8 per cent.
On the other hand, Hoyne (1935) e-nd Hoyne, Tfolf end Prim (1935) have 
reported two series o f  American cases in which the males formed two-thirds 
o f  the cases. (In the f ir s t  paper 66 per cent, and in the second paper
60.1 per cent, were males). In none o f  the series o f  cases mentioned has 
one important factor been taken into account, namely the sex constitution 
o f  the population at risk. When this is  done with my own series o f cases 
we find that the sex distribution i s  almost the same in cases o f  
erysipelas as i t  i s  in the population o f Glasgow. Taking the census 
figures for 193  ^ — a suitable year since i t  fa l ls  mid-way between the 
beginning and end o f our survey period — we find that 48.2 per cent, o f  
the population are males and 51*8 per cent, females. In other words, the 
disease shows a similar incidence in the two sexes.
The distribution o f the cases in  different age groups i s  shown 
in Table 5 Figure 5* I t  i s  apparent that the age incidence shows 
some curious features. Many acute in fectious diseases show their 
highest morbidity in the age group 0-10 years. Here we find the maximal 
incidence between 41 end 60 (males 41.3 per cent, j females 37*0 per cent.;
both sexes 39*4 per cent.). The comparatively low incidence in the /
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the age groups 11-30 years (19*6 per cent.) i s  surprising, for  i t  i s  at 
these ages that cuts and minor abrasions are most commonly seen. Further, 
normal expectation would lead us to suppose that in this age group exposure
o f  the male to minor degrees o f  skin injury, and in turn to l ia b i l i t y  to
erysipelas, would exceed that o f  the female. Analysis o f  the sex 
incidence in this particular age group (11 -30 years) shows that o f 1,310 
cases 508 (38»B per cent.) sre males and 802 ( 61.2 per cent.) are females. 
In the general population o f Glasgow there were, in 193^> 348,626 persons
between the age o f  11 and 30 years: the proportion o f males was thus 48
per cent.
TABLE 5.
Age and Sex Constitution o f  Erysipelas.
6,626 c ases : 1928- 1938*
Age
Group
(Tears)
Male Cases. Female Cases. Total Cases.
0-1
1-5
6-10
127 (3-9)
128 ( 3 . 9) 
76 ( 2. 4)
120 (3-5)
132 (3-9) 
67 ( 2.0)
247 ( 3-7) 
260 ( 3 . 9)
143 (2.2)
Tojjal 
under 10 . 331 (10. 2) 319 (9-4) 650 (9-8)
11-20
21-30 
XI-40 
41-50 
51-60 
61-70 
over 70
203 ( 6. 3) 
335 (9-4) 
462 (14.3)
674 ( 20. 7) 
677 ( 20. 8)
419 (1 3 . 0) 
169 ( 5. 2)
319 (9.4) 
48j  (14 . 3) 
468 (1 7 . 8) 
667 (19.7) 
596 (1 7 . 6 )
353 (10.4) 
181 ( 5- 3)
1 P ' - ‘ ' 1 ' '
522 (7-9) 
788 (11.9) 
933 (14.1) 
1,341 (20.2) 
1,273 (19.2) 
772 (11.6) 
350 ( 5-3)
Totals 3,240 (99-9) 3,386 (99. 9) 6,626 (100. 0)
The figures in brackets represent percentages.
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To measure the age-distribution accurately, i t  is  necessary again 
to compare the figures with those o f  the general population. This has been 
done in Table 6: the population o f the City o f  Glasgow for  the census
year o f  1931 ^as again been used. In order to express the figures as
a ’’case—rate” per 10,000 o f  the population, the number o f  cases o f  
erysipelas in each age group has been divided by eleven; for  the 6,626 
cases represent eleven years’ experience o f  the disease. There is  probably 
an increased accuracy in using these figures rather than those for  e. 
single year: any irregularity  in the age-distribution in a particular
year w ill thus be smoothed out. The case rates per 10,000 fo t  the two 
sexes are shown in the form o f a graph in Figure 6.
Examination o f  the Table and o f  the Figure shows f i r s t  the uneven
age-distribution o f  the disease. As with some other acute in fections,
the incidence is  greatest at the extremes o f  l i f e .  Of equal in terest i s  
the dissim ilarity o f  incidence in the two sexes. The greater frequency o f 
the disease in females between 11 and 30 years and the lower frequency in 
this sex over the age o f  50 years i s  well depicted. Such an inequality 
cannot be easily explained for, as has already been suggested, one would 
have expected the male cases to exceed the female more especially in the 
young adult age group. I t  i s  not intended to discuss this feature in the 
present work, although i t  is  clearly o f  some interest in i t s e l f .  Without 
further analysis, however, i t  might lead to the suggestion that simple 
streptococcal in fection  o f  a skin wound or abrasion is  not the entire 
explanation o f  the etiology o f erysipelas.
-  19 -
' o !:n iiW,j
9 II
C/lc4
T3
o «
To
&PH
<+H
o
CD
o
G
CO
•HaGn
cotadcm
CD
,G
E-»
PXa)
E-h
<0
to
to
(OCO
U)
to
3
o
tJaj
>
-P
C3
S3
O
•H
-Po3
PH
o
P-.
CD
■G
P
<P
O
O
O
O
(0Pr
to
CO
-p
a3PS
CO
COaj
o
1
1
1
1 CD P  O  
I P  CO o
. !  £  a o .  
w | o
CO t r-j
K
O  C\J ^  ^  r l  ON ON i n  ^
K  o  cvi r - \  R l  W  1^ - 
• • • • • • • • #  •
O K t^ H  CM UN ON O  O  ON 
i—1 H  H
B
o
th
 
S
e
C
a
s
e
s
 
(M
e
a
n
 
T
e
a
r
)
.
UN H 1 UN CM stf KN CO CM 
NO 00 UN S  H  CO 
ITi h  O  LTN ,—| ^  O  CM CO rH 
•5J1VO O ' l i C O l A o N r l S  
• • • •  • • • • •  • 
cm K i K i N p ^ o j i n o  r-H 
W  w  H  'j* CO Oj H  ^  IM  
rH H
1--
--
--
--
-
[ 
P
o
p
u
­
l
a
t
i
o
n
i
CM ^ V D O n N I ^ O S H C O  H  
u n  cm KN o p  M  c\i h  P i  u \  m  
O O r l r H ^ H W l A W H ^
o q o h * ^  o  r -^ oo h  k «- cm
c o r ^ o  CN C \  LT\ m  H  ^  K'N 
H  r l  rH rH rH H
e
s
H
a
t
e
p
e
r
1
0
,0
0
0 CQ ON OO M  N  ^  O  UN LCN CM 
U N O  H  ( N  K l  O  ^  M  l A  
• • • • • • « • •  •
O  K l  H  CO UN OO ON ON 00  
H
Fe
in
 
a
li
C
a
s
e
s
(
M
e
a
n
)
(
T
e
a
r
) O  ON H  t  I f '  OO ON 
ON O  ON UN S -  H  O  ^  
O O  ON O  O  H* OJ o o  ON UN 
ON O  O  O  O n UN r^- H  O  
• « • • • • • « •  • 
O  CM NO QN KN CM O  H* CM NO 
H  H  C\l ^  ^  ' C  UN K j  H
T
o
t
a
l 
C
a
s
e
s
 
(1
1 
T
e
a
rs
)
^
P  ^  ON KN CQ r '-  NO KN H  
CO KN NO H  op  NJ VO On UN CO 
H  H  K I  ^  H 1 NO UN KN H
i
P
o
p
u
­
la
t
i
o
n H  ^  {> K 'l O  KN H  ' i 1 OO CO
c l '  ^  ^  0 0  ° °  D :  P '
F \ 0 O ' U 3  O n r l  NO 0O 00  KN CO
O  CQ rH OO o  ^  ,Q\ i n  S ,  O n 
H  T A  UN ON o  OO NO UN ^  H
R
a
t
e
p
e
r
1
0
,0
0
0 UN NO W  ^  CO ON H  O  CM UN 
O n On K \ O N O  r ^ - O O H ^ P  UN 
• • • • • • • • •  •
o  CM H  H K N U N O N H H  i—1 
H  H  H  H
a
le
s
C
a
s
e
s
(
M
e
a
n
)
(
T
e
a
r
)
i
^  K )  H  UN f f l  N  ^  (J\ NO 
UN ^  O n r# N  CM LT\ o  KN 
H* KN O  UN CM O  C'-- H 1 ON NO 
UN NO ON H 1 N  O  CM UN o  KN 
• • •  • • • • « •  • 
rH H  ^  0 0  N  W  H  H  OO UN 
rH rH rH CM H* NO NO N l  pH
M
"
T
o
t
a
l 
C
a
s
e
s
 
(1
1 
T
e
a
r
s
)
I 
'
F'" 00 NO KN UN CM N  0 \  CN 
CM CM r ^ O Q N O  r«» |N. H  NO 
rH rH N  R  ^  ^  VO 9  H
P
o
p
u
-
 
! 
l
a
t
i
o
n
i i
d P Q ^ ' l P ^ O Q O N O  KN 
H* NO UN f*N CM ON KN ^  m  OO 
UN CM H 1 UN o  UN NO KN K -  CM
•> *\ *V •»
o  ON CM UN O  CM CM UN CM KN 
rH K ' N U N O N O N r ' - N O U N K N H
A
g
e
G
r
o
u
p
H  UN H  &  §  l?\ n3  R -  +
1 1 v 1 c 1 I I  1 1 1
ooo
Males
(years.)
-  20 -
The graph (Fig. 6) suggested one further feature to me, namely, i t s  
sim ilarity to the curve o f  incidence for pneumonia. Case rates for this 
la tte r  disease are d if f ic u lt  to obtain. Britten (1942) has recently 
reported from America what must be regarded as fa ir ly  accurate figures. 
They were obtained from a National Health Survey in which over a period 
o f  time accurate sickness records o f  a cross section o f the population 
were obtained. Fig. 7 shows a curve drawn from the data supplied 
in his paper: fo r  comparison the rates (irrespective o f  sex) fo r  the
present series o f  erysipelas cases are shown in the same figure. (I t  
should be noted that B ritten^ rates are nper l , 000n whereas those for  
erysipelas are "per 10,000"). A general sim ilarity between the 
two curves is  apparent.
FIGURE. y.
30 E & Y S I P L L A S
A<je - S p e c if ic  Case R a k e s per 10,000 population  
6 . €>26 c a s e s  (hospitalised) Glasgow 
—  co/J7y0arec/ nr/M ----
P H  E U M O M I A
A^e -  Specific Case Rakes fo r A m e r ic a  per 1.000pop.
(adiTtfcw * seRias )
E r .y s i p e . l a s  (Gfoiyo")
PweunoMift (America)
10
10
o  - i o  - 2 0  - 3 0  -4 .0 - 5 0  - 6 0  - 7 0  - a  o
A G E .  G R O U P
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4. Variations in Severity with Sex and Age.
Erysipelas is  generally regarded as more fatal in the male.
In the present series, among 3*240 males there were 258 deaths (fatality  
rate 7*9 per cent.), while among 3 females there were 23i deaths 
(fatality rate 6.8 per cent.). The difference is  five times its  
standard error and is  therefore significant.
The influence of age upon the fatality rate of erysipelas is  
well known. Ker (1909) stated that the disease was extremely fatal 
in the new-born and that even under 10 years a rate of 11 per cent, could 
be expected. Between 10 and 2P years, however, the fatality rate was 
only about 3 Per cent. Rolleston and Ronaldson (1940) stress the 
severity of the disease at the extremes of li fe . The present series 
provides more detailed evidence to this effect. Almost 80 per cent, of 
all the deaths occur at ages under 10 years and ov^r 50 years. Table 7 
shows the actual totals in the different age groups and Figure 8 depicts 
the curve of the fatality rate with its  two peaks at the extremes of 
l i fe . Separation of the 0-10 years age group into two quinquennia 
(Table 7) shows very clearly that the fatalities occur in the 
younger age group. Again the similarity to pneumonia,'already noted, 
i s  striking.
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Table 7*
Deaths by Sex and Age Group in Erysipelas. 
6,626 Cases ; 1928-1933»
Age Males. Females. Both Sexes.
Group
(Tears) Cases. Deaths. Cases. Deaths. Cases. Deaths.
0-5 255 42 (16.4) 252 50 (19.9) 507 92 (18.0)
6-10 76 0 ( 0.0) 67 1 ( 1.5) 143 1 ( 0 . 7)
0-10 33L 42 (12.6) 319 51 (16.0) 650 93 (14. 3)
11-20 203 3 ( 1.5) 319 1 ( 0.3) 522 4 ( 0 . 8)
21-30 335 10 ( 3-3) 483 9 ( 1.9) 788 19 ( 2. 4)
31-40 462 11 ( 2.4) 468 15 ( 3-2) 930 26 ( 2. 8)
41-50 674 28 ( 4.2) 667 23 ( 3.4) 1,341 51 ( 3 . 8)
51-60 677 59 ( 8.6) 596 42 ( 7.1) 1,273 101 ( 7. 9)
61-70 419 63 (15. 0) 353 46 (13. 1) 772 109 (14.1)
over 70 169 42 (24.8) 181 44 (24.2) 350 86 (24.5)
FI 6 U R. EL 6
Act. Sp e c if i c  Fa t a l it y  Rate.%  
E r y s i p e l a s
6.626 Cases 1 928-36
I- 2 3 -
I t  is  dear from a study of these figures that the fatality 
rate of any series of cases will bear a direct relationship to its  
age-distribution and that, in fact, the fluctuations in the annual 
fatality rates might well be explained by variations in the age and
i
sex constitution of the persons attacked in any year.
Summary and Condusions. .
This brief review of the natural behaviour of erysipdas has an 
obvious bearing upon the study of its  therapy. The fnformation gained 
may be summarised in the following way;-
(a) The fatality rate of erysipdas is  not high. It  is  influenced 
particularly by age, sex and season. A simple reduction in the 
fatality rate will not be a satisfactoiy method of assessing 
the efficeay of a new method of treatment.
(b) The variations in the annud and seasond severity of the 
disease make the comparison of one group of cases with 
another, treated at a different time, open to serious objection.
(c) The ddiberate selection of cases for therapeutic tr id  will 
be unsatisfactory unless sdection is  made of the more fa td  
disease seen at the extremes of l i fe . In such cases, however, 
complicating factors due to age done may so d te r  the course 
of the disease that the benefidd effect of a new method of 
treatment is  masked.
Consideration of these characteristics convinced me that, in the 
investigation of methods of treatment for erysipdas, the following 
conditions must be satisfied:-
(i) The investigation should indude all cases of both sexes 
and at all ages.
(ii) Any new method of treatment should be controlled concurrently
by comparing its  effect with a standard method of treatment 
administered to dtem ate cases.
(iii) /
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( iii)  The trial period should be reasonably long so that seasonal 
variations in severity could be excluded.
(iv) The trial should continue until a large number of cases 
had been collected, in order that the results could be 
analysed in sex and age groups.
(v) The use of the fatality rate as a means of assessing 
the results of treatment should, at least on primary 
analysis, be avoided. It  would be advisable to choose 
observable characteristics of the disease and, by 
carefully recording the daily changes which occurred in 
them, to collect a large number of observations on the 
course of the disease in both a treated and untreated 
series of cases. The efficacy of the treatment could 
then be gauged even in groups of persons where the 
attack was mild.
(vi) The results should be capable of expression in figures 
so that methods of statistical analysis could be 
applied.
-  25 -
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CHAPTER III .
The Choice end Definition of the Factors
of Assessment.
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Since the fa ta lity  rates were not to be used as a criterion  o f  the 
value o f  a new method o f treatment, the following ’’Factors o f 
Assessment'1 were chosen.
The Duration, in Days, o f  the Spread o f  the Local Lesion.
A characteristic o f erysipelas, which is  i t s e l f  o f  diagnostic 
importance, is  the tendency for  the lesion to spread. E ffective therapy 
should result in more rapid halting o f the advancing lesion , fo r  spread 
i s  d irect evidence o f  the activ ity  o f the invading streptococcus.
The "cessation o f  spread" has often been mentioned as an indication o f  
the e ffica cy  o f  treatment but a il previous writers have contented 
themselves by stating that "most" or "such-and-such a percentage" o f  the 
cases stopped spreading within a certain period o f the in it ia tion  o f 
treatment. A method much to be preferred i s  to compare the actual 
duration o f spread in two groups o f cases.
The method used for estimating the duration o f the spread was to 
mark the edge o f  the lesion when the case was admitted with 0.1 per 
cent, crystal v io le t. Thereafter, examinations were made between 9*3D
a.m. and 11.30  a.m. on each day and, i f  spread had occurred, a fresh 
lin e  was drawn with the paint at the new edge o f  the lesion . From the 
time o f  admission until the morning examination on the following day 
was regarded as one day.
The objection may be made that as crystal v io le t  i s  i t s e l f  an 
antiseptic i t  might exert some loca l e ffect on the lesion . I f  th is is  
so (and i t  seems very unlikely considering the depth o f  the in fection  in 
the skin), i t  may be emphasized that every case, irrespective o f  the 
method o f  treatment, was so demarcated.
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2* Duration, in Days, of Primary Pyrexia.
Fever is  a usual characteristic of most cases of erysipelas. In 
most acute infections the return of the temperature to normal has always 
been regarded as an index of recovery. Used alone i t  would be a 
dangerous factor of assessment, for a new drug might well produce an 
antipyretic effect; used in conjunction with other criteria, however, 
i t  has the value that i t  is  a measure beyond the influence of the 
observer. The duration was measured in days; the period from admission 
until the morning visit upon the succeeding day was regarded as one day.
3 . Miration, in Days, of Primary Toxaemia.
I f  the term toxaemia be used in no specific sense but merely to 
indicate the presence of a general constitutional upset, i t  is  well 
known that its  manifestation in erysipelas may be profound. The degree 
of toxaemia, however, is  d ifficult to estimate; even with the simple 
and common clinical classification into mild, moderate or severe, there 
is  a large element of personal error. My purpose was to find some way 
of estimating, in a similar way for each case, when toxaemia disappeared. 
Accordingly, the following symptoms and signs of the toxic state were 
chosen: prostration, headache, insomnia, state of tongue, vomiting,
abdominal distension, and delirium. The condition of the patient in 
respect of each of these was noted first on admission and, thereafter, 
each day when the morning visit was paid, until all had disappeared.
Here again the duration was measured in days; the period from admission 
until the morning visit on the succeeding day was regarded as one day.
These three factors will form what might be termed the basis of
assessment of the effect of the new drugs in controlling the disease.
In addition to these, but subsidiary to them, the following figures will 
be used, remembering that they must be used with caution.
4. Complicated Case Rate.
It might be anticipated that the more effective therapy of the acute 
stage of an infection would lead to a lowered incidence of a ll, or of 
certain complications. The careful classification of the complications of 
eiysipelas will be necessary, however, i f  their incidence is  to be 
compared in two groups of cases which receive different treatment, end 
I propose to divide them in the following way:-
(i) Attacking, as i t  does, individuals at the extremes of l i fe , i t  
might be anticipated that patients (especially in the older 
age groups) will show the marks of degenerative changes. In 
such patients the course of any illness might be complicated by 
the appearance of features none of which could be regarded as 
true complications of the disease. An elderly patient who 
suffers from bronchitis and chronic myocardial weakness may be 
cited as an example. Any strain might upset the balance of his 
cardiac mechanism and the fact that auricular fibrillation occurs 
in the course of his erysipelas is  merely an incident in the 
degenerative cardiac process and not a true complication of 
the disease.
(ii) Another group of complications may be noted which are really 
due to the exaggeration of some feature of the erysipelatous 
lesion which is  normally present. A common example in 
eiysipelas of the limbs is  for bullous formation to result in 
extensile local skin necrosis and the formation of shallow 
ulcers, the healing of which may be very slow. Such a process 
is  usually already at work before the case comes under treatment 
although its  occurrence is  difficult to forecast.
(iii)  finally there is  the main group of true complications directly
consequential upon the acute infection. These can be conveniently 
divided into three sub-groups:-
(a) I t  has already been pointed out that there may be severe 
constitutional upset. This may give rise to the appearance 
of wtoxicn complications, such as severe delirium and 
retention of urine. These are not peculiar to erysipelas 
but, since they are regarded as complications of the other 
acute infectious diseases, their description as such 1b 
erysipelas has abundant precedent.
(b) The presence of virulent streptococci in the skin may give 
rise to such complications as inflammation of the associated
lymph glands, the formation of subcutaneous abscesses, and in 
some cases the invasion of the Hood stream. These may be 
regarded as the true complications of the disease.
(c) finally /
(c) finally, in a separate subdivision may be placed 
nephritis* Its  occurrence is  deserving of special 
mention, for as I have already mentioned, the 
sulphonamides are excreted in large part by the 
kidneys. In a disease in which nephritis is  known 
to occur as a complication, the possible deleterious 
effect of the drugs is  worth special attention.
Summarising the above discussion, the following classification of
the complications of erysipelas is  therefore adopted:-
(1) Complications resulting from the presence of some chronic 
disease or degeneration,
(2) Complications resulting from the exaggeration of an element 
of the disease noimally present.
(3) Complications resulting from the acute infectious process.
(a) Toxic.
(b) Invasive and pyogenic.
(c) Renal.
5* fatality Rate.
Although i t  has been decided to exclude the comparison of fatality  
rates as a primary factor of assessment, beneficial treatment should 
result in fewer deaths and a study of these may produce valuable 
information as to the types of case which do not respond to the new 
treatment. The cases which die will, therefore, be analysed separately.
In addition to this the comparison of fatality rates will be made by a 
study of the trend of the disease as it  is  seen in this country over 
a more prolonged period.
6. Relapse and Recurrence.
Both relapse and recurrence are frequently encountered in erysipelas. 
The effect of a new method of treatment might influence their occurrence 
and observations thereon must, therefore, be recorded. The terms 
themselves require definition. In accordance with precedent the term
/
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term relapse i s  used to indicate a fresh attack o f  erysipelas occurring 
within a short period o f  the apparent cure o f  the f i r s t  attack and before 
the dismissal o f  the patient from hospital. Recurrence (or Recurrent 
Case) i s  used to indicate an attack developing in a person who gives a 
history o f  a previous attack o f the disease, possibly many years before.
7. Duration, in Days, o f Residence in Hospital.
Provided i t  i s  not prolonged purely by reason o f in fe c t iv ity , the 
duration o f  a patient’ s stay in a fever hospital forms a good guide to 
the severity o f  an in fection . Two conditions operate to hasten dismissal.
In the f i r s t  place there is  no v isitation  by relatives; and secondly
there is  a constant demand from the Health Authorities for  accommodation. 
Improved treatment might, therefore, result in more rapid dismissal o f  
the patient.
The fin a l analysis o f  the cases used in this investigation o f  the 
treatment o f  erysipelas by chemotherapeutic drugs w ill rest upon a 
consideration o f  their e ffe ct  on these seven characteristics or, as they 
are better termed, ’’Factors o f Assessment. ”
To enable the analysis to be as complete as possible the fo lio  wing
special sheet and card were used:-
1. Special Case Sheet.
2. Copeland Chatterson Punch Card.
Name Primary
Description o f  In it ia l Lesion
Site:
Extent:
Pain ?:
Oedema ?: 
Sloughing ?: 
Phlegmonous ? 
Adenitis ?:
Recurrent
Idiopathic
Surgical
Day o f Illness 1 1 2
Prostration 
Headache 
Delirium 
Insomnia 
Tongue 
Vomiting
Abdominal Distension 
Diarrhoea 
Blood Pressure 
j White Bl.C.
| Daily -  Spread 
j Pain present 
Tenderness present 
Oedema
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CHAPTER IV.
The Plan o f  the Experiment.
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In carrying out a study of the effect of a drug on any disease 
i t  is  necessary to avoid the possible influence of any factor other than 
the material actually under test. So far as possible, therefore, every 
case admitted to the eiysipelas wards during the period of the 
investigation received a "basal treatment", the details of which were 
as follows.
Basal Treatment.
On admission the patient was given a bed-bath, after which his 
temperature, pulse and respirations were recorded. He was then given 
a simple soap and water enema. Throughout his stay the only aperients 
used were Liquid Paraffin or Liquid Extract of Cascara Sa&rada.
Each patient received the normal hospital diet, the essentials of 
which were:-
(i) During the febrile period the diet was almost entirely fluid — 
milk, Imperial drink, orange and lemon drinks and fruit je llies.
Water was given freely, from four to five pints being the 
amount usually consumed daily.
(ii)  After the temperature settled the diet was gradually increased, 
to begin with by the addition of porridge and milk, puddings, 
fish and chicken.
(iii)  As improvement was maintained the diet was increased by the
addition of mince, potatoes, stew, etc., and for the remainder 
of his stay in hospital the patient received an ordinaiy 
diet.
Certain specified drugs were prescribed for the relief of symptoms 
which previous experience of the disease led me to expect would arise. 
Acetyl-salycylic Acid was given to relieve headache or malaise. A powder 
containing Aspirin, Phenacetin and Caffeine was given for minor degrees
of insomnia. Dover* s powders, Syrup of Chloral, or Paraldehyde were 
prescribed for more severe complaints of sleeplessness. I f  pain was /
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was severe, delirium present, or insomnia intractable, morphine sulphate 
with or without hyoscine hydrobromide, was given by subcutanoue injection. 
Unless as required fox the treatment of some accompanying disease 
unassociated with the erysipelas, no other drugs were used.
A specimen of urine was examined daily during the febrile period 
and thereafter as often as appeared necessary. The specific gravity, 
reaction, and the presence or absence of albumin, blood or sugar were 
recorded. When i t  appeared necessary, specimens were examined 
mi cro scopi cally.
The local lesion received no form of direct treatment other than 
that about to be described.
Methods of Treatment prescribed for the Cure of the Infection.
(a) Control Methods of Treatment.
(i) Ultra-violet Light:
When the trial was begun the standard method of treatment in the 
hospital was to irradiate the entire spreading margin of the lesion by 
means of a portable ultra-violet light lamp. This method of treatment had 
been reported on favourably by Ude and Platou (193D)> Davidson (1932)# 
Nightingale and Starr (193^) > Sutherland and Day (1935) Holmes (1938)* 
Treatment was administered in the following manner.
The lamp (the erythema dose of which was known) was held by the nurse 
12-18 inches from, and at right angles to the spreading margin of the 
lesion and one-and-a-half erythema doses were administered. I f  the lesion 
were of some extent i t  was necessary to change the position of the lamp 
and repeat the treatment sufficiently often to ensure that all the /
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the margins of the lesion were irradiated. In cases of facial erysipelas 
the eyes were covered during treatment by two pads made from several 
thicknesses of gauze. I f  the lesion remained active, and extensive 
spread occurred, the entire treatment was repeated — usually at 
intervals of not less than twenty-four hours.
(ii) Scarlet Fever Antitoxin:
The demonstration that the haemolytic streptococcus elaborated 
an exotoxin led to the production of a neutralising antitoxin which was 
soon utilised successfully in the treatment of cases of scarlet fever.
In the belief that specific streptococci were responsible for the 
different streptococcal infections, Birkhaug (1927,19^3) introduced an 
"Erysipelas Antitoxin" with which successful results were claimed in 
the treatment of erysipelas, (Symmers and Lewis, 193^)*
Bacteriological opinion has never entirely subscribed to the 
theory of "specificity" of streptococcal infections but, especially in 
Britain, has tended towards a "unitarian" view — namely, that the same 
streptococcus could be responsible for all clinical forms of 
streptococcal disease (Okell, 1932)* Indeed, Parish and Okell (1928) 
had produced evidence to show that, by using the toxin from strains of 
streptococci Isolated from scarlet fever sources, an antitoxin could be 
produced which contained all the neutralising substances. Scarlet 
fever antitoxin was accordingly used fairly extensively for a period 
in this country for the treatment of erysipelas. Baxter (193^) 
reported favourably on its  use in the treatment of a small number of 
cases at Buchill Fever Hospital.
In /
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In the present experiment the serum used was that marketed by- 
Messrs. Burroughs, Wellcome as "Concentrated Streptococcus (Scarlet Fever) 
Antitoxin, Globulin Fraction." I t  was administered intravenously or 
intramuscularly; the standard dose being "JO c.c. (equal to 30,000 units). 
Before the administration of antitoxin intravenously patients were 
desensitised by the administration of fractional doses of serum. At half- 
hourly intervals 0.25 c .c ., 0 .5  c .c ., and 1 c.c. of serum was injected 
subcutaneously and, i f  after a further half-hour no local or general 
reaction had occurred, the main dose of serum was then given. In a few 
cases a further dose of 30 c. c. was given on the following day i f  no 
improvement in the clinical condition of the patient had been noted.
( i i i ) "R.I. Powders" :
At a later stage of the inves tigation I decided that valuable 
information might be obtained i f  the course of erysipelas could be 
followed in cases receiving no "specific" treatment. The lack of the 
provision of some form of treatment would have aroused comment from 
patients, nursing staff and doctors. To circumvent this, powders were 
prepared privately which contained 15 grains of sugar of milk. These 
were supplied to the wards without comment, other than that they were 
"another new method of treatment." They were labelled "R .I. Powders" 
and were administered at four-hourly intervals. Case records were 
compiled in a manner exactly similar to those made with more orthodox 
therapy.
As a precaution against harm arising from the use of the powders, I 
decided that patients receiving them should be carefully reviewed at the
end of twelve, twenty-four, and forty-eight hours. I f  i t  appeared that the 
condition of the patient was deteriorating at any of these earlier
/
earlier examinations, and in any case which was s till acutely i l l  at 
forty-eight hours, treatment with the powders was stopped and 
sulphonamide therapy immediately instituted.
(b) Chemotherapy.
(i) Sulphonamido-Chrysoidine:
The drug used was the original dye marketed as "Prontosil Red" by- 
Messrs. Bayer Products, Limited. At the beginning of the experiment 
the drug was supplied in the form of tablets containing 0 .3  grammes 
but later tablets containing 0.5 grammes were used. When first tested, 
reports of its  use in erysipelas were both scanty and unsatisfactory.
The drug was therefore used in small dosage by mouth and its  exhibition 
stopped at the end of the acute phase of the disease. As experience 
with the drug was obtained the dosage was increased and continued into 
the convalescent period. A few of the early cases received the 
drug parenterally.
In a small series of cases the drug was combined with ultra<- 
violet light.
(ii)  Sulphanilamide:
amino-benzene-sulphonamide was used as marketed by Messrs. Evans, 
Sons, Lescher and Webb under the trade name of "Streptocide. " This 
was first supplied in the fora of tablets containing 0 .5  grammes, but 
arrangements were made for the supply of the drug in powder form so 
that different dosage schedules could be adopted. Throughout the stages 
of the experiment the drug was administered by mouth at four-hourly 
intervals until cure was established; a lower scale of dosage was then
adopted and was continued until the patient1 s dismissal from hospital.
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(iii)  Ben zyl-Sulphanil amide;
Tests were carried out with £ -ben xyl-amino-benzene-sulphon amide, 
which was marketed by Messrs. Pharmaceutical Products (May & Baker)
Limited as "Proseptasine, M & B 125". This drug was in the form of 
tablets containing 0.5 grammes. Here again the drug was administered 
by mouth at four-hourly intervals until cure was established and, 
thereafter, in reduced dosage until the dismissal of the patient.
(iv) Carbo xy- Sulp hami do- Chry so i  din e:
This drug was marketed as "Rubiazol" and was supplied by Messrs. 
Roussel. I t  was in the form of tablets, each containing 0.2 grammes.
Again, administration was ty means of four-hourly doses ty mouth until 
cure was established and thereafter in reduced dosage until the 
dismissal of the patient.
With, the exception of a few early cases who received a soluble 
form of sulphonamido-chrysoidine intramuscularly, all of the chemo­
therapeutic agents were thus administered by mouth, lflhen the drugs were 
in the form of tablets they were always crushed and were usually given with 
milk or syrup as a vehicle of administration.
The therapeutic trial was begun in June 193^ 811 continued until 
the end of 19395 so that i t  covers a period of three and a half years.
The inves'tigation was broken up into "stages", of which there were five.
Although each of these "stages" was self-contained and can therefore be 
separately analysed, one of the methods of treatment was usually carried
over from the previous stage into the new stage, so that, should the 
necessity arise, i t  would be possible to compare the results obtained at 
different periods of the investigation.
The /
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The methods of treatment and the numbers of cases used in the 
different "stages*1 were as follows: -
Stage 1 : Number of Cases ^L2,
Control Methods of Treatment*
(i) Ultra-violet light.
(ii)  Scarlet Fever antitoxin.
Chemotherapy.
(i) Sulphonamido-chrysoidine.
(ii)  A combination of sulphonamido-chrysoidine and 
ultra-violet light.
Stage 2 : Number of Cases 270.
Control Methods of Treatment.
(i) Ultra-violet light.
Chemotherapy.
(1) Sulphanilamide.
Stage 3 ; Number of Cases 242.
Chemotherapy only.
Study of the effects of varying dosage scales o f :-
Sulp hon ami do- chry so i  din e
Sulphanil ami de
Ben zyl- sulp hanil ami de.
Stage 4 : Number of Cases 204.
Control Methods of Treatment.
(i) Ultra-violet light.
(ii)  Powders.
Chemotherapy.
(i) Sulphonamido-chrysoidine.
Stage 5 • Number of Cases 1/9*
Chemotherapy only.
(ij Sulphonamido-chrysoidine.
(ii)  Carboxy-sulphamido-chrysoidine.
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At the beginning of each stage of the experiment a large card 
was hung in the ward, divided into parallel columns according to the
number of methods of treatment under test. When the diagnosis of 
erysipelas was confirmed cases were entered in t he different treatment 
columns strictly in the order of their admission to hospital. The 
particular method of treatment which they received was, therefore, 
le ft  entirely to chance.
Two departures from this general rule must be recorded:-
(a) After the first two stages of the experiment had been carried out, 
sufficient evidence was accumulated to show that the sulphonamides had 
a beneficial effect. I t  was fe lt that to withhold the drugs from those 
patients under 5 years, in whom the disease often ran a rapid and severe 
course, was unjustifiable. All cases, therefore, in this age group 
admitted after August 1937 were given a sulphonemide. The cases in 
this age group will be analysed separately.
(b) After evidence of the value of the drugs had been obtained i t  was 
thought that i t  was unethical to withhold them from any person who was 
showing entire lack of response to a control method of treatment. 
Accordingly, when the daily assessment of the course of the disease was 
being made, severe cases were sometimes "transferred" to sulphonemide 
treatment. I wish to emphasise, however, that this was done only after 
the control method of treatment had been given a trial of at least 
twelve, and usually twenty-four hours. Each case received primarily 
the appropriate treatment according to the order of its  admission.
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CHAPTER V.
Analysis of the Results of Treatment. 
Preface.
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It has already been explained that, when methods of treatment 
are being compared, i t  is  essential to show the distribution of 
the cases treated in respect of any factors which may influence the 
results. The interpolation of such data in the text/ seems to me 
to interrupt the train of thought without serving any purpose 
germane to the actual discussion of the results. They have, therefore, 
been collected together in the form of appendices. These tables 
show the distribution of the following characteristics in the 
cases which comprise the experiment: age, sex, duration in days i l l
prior to admission, proportion of primary and recurrent attacks, 
proportion of idiopathic attacks, site of lesion, and the presence 
of; associated diseases or degenerations.
CHAPTER V.
Part 1.
Is Chemotherapy with Sulphonamides effective
in Erysipelas?
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My first purpose is  to attempt to evaluate the effect of 
the sulphonamide group of drugs in the treatment of erysipelas. 
From Table 8, which shows in a concise way the different stages 
of the experiment, i t  will be seen that in' three of then a 
direct comparison was made between the effect of ultra-violet 
light and chemotherapy with either sulphonamido-chrysoidine or 
sulphanilamide (Stages 1, 2 and 4). Grouped together they 
comprise a series of 618 cases, of which ^36 received irradiation 
with ultra-violet light and %L2 received chemotherapy. In point 
of time the cases in stage 1 were treated during 193^5 those 
in stage 2 in 1937$ those in stage 4 in 1933* la each stage
the allocation of the case to either method of treatment was a
random one. The cases were not selected in any way and every 
patient admitted during these periods in whom the diagnosis of 
erysipelas was confirmed is  included. The method of treatment 
with ultra-violet light remained constant throughout the whole 
of this period.
In the group receiving chemotherapy there was both a change 
of drug and a change in its  method of administration (see Chapter 
i d . These changes, however, do not invalidate a comparison
between the two methods of treatment, provided that the question 
which we set out to answer is  simply "are the sulphonamides
effective in the treatment of erysipelas?"
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TABLE 8.
The Stages of a Therapeutic Trial in Erysipelas.
Stage
No.
of
Cases
Treatment
of
Controls
No.
of
Cases
Chemotherapy
No.
of
Cases
1936
I .
1937
312
Ultra-violet
Light.
Scarlet Fever 
Antitoxin.
104
48
Sulphonami do- 
chrysoidine
Sulphonamido- 
chxypoldine.
Ultra-violet
Light.
106
54
n .  1937 270 Ultra-violetLight 135 Sulphanil ami de 135
nr. 1938 242 - -
Varying dosage 
of
Sulphonamido- 
chrysoidine 
Sulphanil amide 
Benzyl-Sulph­
anil amide
60
122
60
iv. 1938 204
Ultra-violet
Light
R.I. Powders
67
66
Sulphonamido-
chrysoidine A
1938
V.
1939
r
179 - -
Sulp honami do- 
chrysoidine
Carboxy- 
sulphon ami do- 
chrysoidine
90
89
Totals: 1207 420 787
Nojbe: To the total number shown in Col. 2 (1207) must be added children
under 5 years of age who were admitted during 1938-39 wh° were not 
allocated to the alternating series.
It is  submitted, therefore, that the group is  a satisfactory- 
sample of the disease as seen during a period of three years end forms 
an adequate series of cases for a direct comparison to he made between 
the effect of a standard method of treatment and that of chemotherapy 
with sulphonamides. Table 9 shows, for the two groups of cases, the 
period in days which elapsed before the cessation of (i) spread of the 
lesion; (ii) primary pyrexLa; (iii)  toxaemia. In compiling the tables 
no exclusions have been made. The inclusion of the following cases is  
mentioned specifically:- 
(a) Deaths.
From a statistical point of view i t  is  desirable that these should 
be shown in the tables. The exclusion of any cases from analytical 
tables always raises the doubt that by so doing the results are affected 
in some way perhaps not apparent to the investigator. In each part 
of the table, therefore, the cases which subsequently died have been 
shown in brackets in the column appropriate to the duration in each
i
of them of the three factors of assessment.
(b) Cases in which treatment was changed.
It  has already been pointed out that the clinical investigation 
of any new therapeutic measure may reach a stage when i t  becomes apparent 
that the new treatment is  good or bad. Frequently, when its  effect is  
beneficial this stage is  reached before i t  is  thought desirable that the 
controlled method of investigation should be discontinued. Unlike the 
laboratory worker, the clinician is , thereafter, placed in the position 
of choosing between scientific accuracy and his patient* s wellbeing.
After the first stage of the present investigation was completed and /
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and analysed (Snodgrass and Anderson, 1937) there was no doubt that 
chemotherapy had a beneficial effect in erysipelas. In later stages, 
therefore, patients who appeared to be deteriorating on the control 
method of treatment were classified as "failed ultra-violet light" and 
a sulphonamide drug was administered. In stage 1, three patients; 
in stage 2, thirteen patients; and in stage 4, thirty-eight patients 
had their treatment so changed.
The inclusion of such cases in the tables under the heading 
"Treatment with Ultra-violet Light" does not, I submit, invalidate 
the comparison. I f  anything, i t  tends to weigh the results against 
chemotherapy and in favour of ultra-violet light.
(c) Those Cases which did not show spread, pyrexia or toxaemia after 
admission to hospital.
In the first place i t  must be pointed out that i t  does not 
necessarily follow that, because a case presents neither fever nor 
toxicity, i t  will also fail to show spread of the local lesion. This is  
in fact not true and, although i t  may be accepted as a generalisation that 
those cases in which fever or toxaemia is  not observed in hospital form a 
group of milder cases, several of than did show an active erysipelas. In 
the second place, the cessation of spread after admission to hospital 
might, on first thoughts, be attributed entirely to efficacious therapy.
It  will be appreciated, however, that although beneficial treatment will
result in a larger proportion of cases showing no local spread in hospitel, 
a certain residuum here too will consist of cases which, without
treatment at all, would have ceased spreading coincidentally with their
coming under observation. This point will be discussed again when I
/
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I deal with the results obtained when no specific treatment 
was administered. At present I merely wish to emphasise that, 
in calculating proportions for comparison, those cases are 
included in which any of the factors of assessment was not 
present on or did not progress after admission to hospital 
and that the percentages given are those of the total 
number in the treatment group.
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TABLE 9.
Duration, in Days, of the Presence of the three main Factors 
of Assessment.
(i) Duration, in days, of spread of erysipelas.
Days 0 1 2 3 4 5 6 7 Ovjpr Total
Chemo­
therapy
161
( 3)
120
( 5)
25
(0)
5
:d
1
(0)
0 0 0 0 3L2
(9)
U.V. 97 68 53 42 23 14 4 4 1 336
Light (1) ( 3) (2) Q-) (1) (o) (0) (2) (0) (1 0 ).
(ii) Duration, in days, of Primary Pyrexia.
Days 0 1 2 3 4 5 6 7 Over
7
Total
Chemo­
therapy
19
(0)
127
(3)
109
(4)
34
:2)
12
(0)
8
(o)
3
(o)
0 0 312
(9)
U.V.
Light
29
(0)
58
(D
64
(0)
42
(2)
42
(3)
20
(o)
25
(1)
11
(1)
15
(2)
336
(10)
( iii)  Duration, in days, of Evidence of Toxaemia.
Days 0 1 2 3 4 5 6 7 Over
7
Total
Chemo­
therapy
13
(0)
47
(2)
110
(2)
81
( 2)
34
. ( 1)
17
(1)
7
(1 )
2
(0)
1
(o)
312
(9)
U.V.
Light
18
(0)
35
(l)
65
(0)
54
(1)
46
(1)
3^
(2)
20
(1)
17
(1)
15
(3)
336
(10)
Mote: In each of the three tables the figures in brackets represent the 
duration of the particular factor of assessment in those patients 
who died.
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Record of Results.
1. The duration, in days, of spread, pyrexia and toxaemia.
The figures in Table 9 make i t  dear that those cases which received 
chemotherapy showed a more rapid cessation of the three factors of 
assessment. This is  emphasised by the following percentages:-
Chemotherapy U.V. Light
per cent. per cent.
Cases showing no spread
after 24 hours in hospital . . .  $0.1  5^
Cases showing no fever
after 48 hours in hospital . . .  81*7 49.4
Cases showing no toxaemia
after 72 hours in hospital . . .  80*7 55* ^
The percentage differences in the above table are striking and all are 
in favour of chemotherapy.
I f  we how examine the figures for those who showed a longer 
duration of the factors we find that they are no less convincing..
After four days in hospital:
Chemotherapy U.V. Light,
per cent. per cent.
Spread continuing . . .  0 7*5
PyrexLa continuing . . .  3.5  23*4
Toxaemia continuing . . .  8.7  28.8
The rates of disappearance of the three factors of assessment are well 
shown in Tigs. l-*5> where the results are given in the form of a 
cumulative frequency distribution.
It is  obvious that there is  a very great similarity in the rate 
of disappearance of the three factors of assessment when sulphonamides
are used (Fig. 1). The effect of the drug seems very definitely to be, 
first, localisation of the lesion itse lf, then, as spread ceases, the /
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the temperature falls and finally toxic signs disappear. This shows 
very clearly that the action of sulphonamides is  not due to any antipyretic 
effect and suggests, as one would have imagined, that the drugs have no 
direct antitoxic effect. Their action is  primarily against the lesion 
its e lf ; when local cure has been established the subsidence of fever 
and toxaemia follow. In this respect they differ from ultra-violet light, 
the graph for which (Fig. 2) does not display the same even trend.
Again, however, we note that the primary response is  a cessation of spread, 
albeit considerably more slowly than with chemotherapy. Figure 2 also 
shows that with ultra-violet light, pyrexia and toxaemia subside more 
slowly. This would seem to suggest that the main effect of ultra-violet 
light is  local; that this local action is  not "curative" to the same 
extent since the interval between cessation of spread and cessation of 
the other two factors is  longer; and, since the rates of the . 
disappearance of fever and toxaemia so closely approximate that the local 
stimulation may have some slight effect in diminishing the general 
toxaemia.
Figures ^,4  and 5 show that each factor of assessment abated more 
rapidly in those cases which received chemotherapy.
Could these differences have arisen from the normal fluctuations 
due to chance sampling? The significance may most easily be tested by 
surveying the results which had accrued in respect of each factor of 
assessment after two days in hospital. The following figures are obtained:-
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1. Spread:
Chemotherapy. U.V. Light. 
Number ceased J )6 218
Number continuing 6 88
2. Pyrexia:
Number apyrexial 255
Number pyrexial 57 155
3 . Toxaemia:
Number non-toxic 1/0 118
Number toxic 142 188
These figures are susceptible to examination by a chi-square test
of significance: the following results are obtained: -
X2 n P
1. Spread 84.365 1 < 0.001
2. Pyrexia 7L.805 1 < 0.001
. Toxaemia 16.256 1 < 0.001
The values for P all indicate that the differences which were 
observed between the two groups in respect of the three main factors 
of assessment are outside the limits usually assigned to chance. Further, 
since all three are in favour of chemotherapy the X^  values may be 
summated (172.426): n now equals 3 P equals <0.001. Such a
distribution of figures as that obtained would have occurred by chance 
even less frequently than once in a thousand times.
finally, the complete figures in respect of the duration in days of 
spread in the two treatment groups (Table 9) were subjected to a nchi-
/
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o
"chi-square" test* I t  was found that X = 110.1: for n = 8,
p
P = less than »01. , (In fact P = -01 for a X of 20.1 so that clearly
P is  very much less than *01). Such results indicate that the 
dissimilarity noted between the two groups is  very much greater than 
could have arisen from the errors of chance sampling.
I.
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2. The Incidence of Complications*
(a.) Complicated Cases.
Among the 3D6 cases treated with ultra-violet light, 69 (22.5 Per 
cent.) showed one or more complication. Among the %L2 cases given 
chemotherapy the equivalent number was 45 (14.4 per cent.).
TABLE 10.
The Incidence o f  Complications in 618 cases o f  Erysipelas.
(arranged according to the d  as si f i  cation described 
in Chapter II )7
Complication
Subdivision.
Chemotherapy. 
Total Cases ?•
U ltra -v iolet
Light.
Total Cases 306.
1 5 7
2 4 6
3 (« ) 3 1
(b> 28 42
(c) 5 13
Total 45 ' 69
(14.42) (2 2 .5%)
Standard Error of Difference
t 3-1
Table 10 shows the complicated cases classified according to the main 
complication present and under the subdivisions previously described 
(Chapter II ) . There was a smaller proportion of complicated cases 
among those treated ty chemotherapy than among those receiving 
ultra-violet light. The difference (8.1 per cent.) has a standard 
brror of 13*106, so that, statistically, i t  is  significant. Analysing /
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Analysing the figures further, we note that those complications which fall 
under subdivisions 1 and 2 are more or less equally represented in the two 
series of cases. I t  will be recalled that these subdivisions record 
complications which are not directly attributable to the presence of an acute 
infectious process. The complications listed as subdivision 3 are enumerated 
in Table 11 which also shows the incidence per cent, of each.
TABLE 11.
The Incidence of Complications in 6l8 
Cases of Erysipelas.
Complications directly due to the presence olr_an acute infectious process 
in the skin.
Chemo therapy Ultra-violet
Light.
Suppurative: 
Adenitis or 
abscess formation 14 (4.5) 19 (6. 2)
Local Suppuration 
or ulceration 2 (0.64) 2 (O.65)
Non-SuDDurative: 
Lymp hadeni ti s 
Blepharitis 
Venous thrombosis 
Bronchopneumonia 
Miscellaneous
7 (2.25) 
1 (0.32) 
1 (0.32) 
1 (0.32) 
10 (3-3)
13 (4.25)
1 (0-33) 
3 (0. 99) 
1 (0 . 33) 
17  (5. 55)
Total 36 (11. 6) 56 (18. 33)
Even in this subdivision the diminution in the number of complicated 
cases among those receiving chemotherapy is  not so striking as one might 
have expected from the results already recorded, although the difference 
in the proportions is  statistically significant. The diminution seems /
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seems to be greater in the group of non-suppurative complications 
of which there are 11*4 per cent, in the cases receiving ultra­
violet light and 6.4 per cent, in those receiving chemotherapy.
The standard error of the difference is  +2.27 which makes i t  
significant. It  may be recalled that no less than ^4 patients 
(presumably the most severe) were transferred from the control method 
of of treatment to the chemotherapeutic group. This might tend 
to weight the results against chemotherapy.
I have separated renal complications into two divisions.
Simple albuminuria occurs not infrequently in the acute febrile stage 
of the disease; this must be separated from true nephritis. The 
latter term has been reserved for cases which showed blood and albumin 
in the urine by chemical test and casts on microscopic examination.
The cases which showed some fora of renal disorder are listed  
in their two divisions in Table 12.
TABLE 12.
 ^ ’ The Incidence of Renal Complications
in 618 Cases of Erysipelas.
Chemotherapy Ultra-violetLight.
Febrile albuminuria 
True nephritis
5
0
5
8 ( 2. 6%)
Febrile albuminuria is  equally present in both series. 
The /
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The incidence of acute nephritis in the cases receiving 
ultra-violet light is  2.6 per cent, with a standard error of 1 0 . 91*
I f  three times the standard, error were used as a test of significance 
i t  is  obvious that for no cases to arise in a series of three hundred 
cases is  not beyond the possibility of chance. The non-occurrence 
of nephritis in the chemotherapeutic group can be regarded as highly 
suggestive, though not perhaps significant, of more effective treatment. 
I t  does, however, indicate that the drugs (used as they were ) had no 
deleterious effect on the kidneys.
With regard to the actual number of true infective complications 
which occurred, i t  may be noted that in the group receiving ultra­
violet light the 56 cases showed 79 complications, a ratio of 1.42 
complications per person; whereas in the chemotherapy group 36 cases 
showed 43 complications, a ratio of 1.19 complications per person.
The accumulated evidence in respect of the incidence of 
complications is , therefore, that, although the differences are not 
great and individually are just within the levels of statistical 
significance, the chemotherapeutic group consistently shows the smaller 
proportion of complications. The actual reduction in suppurative 
complications is  rather disappointing.
3 .' The Incidence of Relapse.
Before considering the incidence of relapses in the cases under 
review i t  must be recalled that the method of administering sulphonamides 
changed during the experimental period. In the first stage, the drug 
(sulphonamido-chrysoidine) was given during the acute stage of the
. /
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the illness only, whereas in the other two stages administration of 
the' sulphonamide was continued into convalescence. Such a change 
might have no effect on the rate of cure of the acute disease but 
might be expected to show an effect on the incidence of relapse.
This must be taken into account in analysing the following figures.
Of the 306 cases receiving ultra-violet light, 21 cases ( 6.9 per 
cent.) relapsed; among the %L2 cases receiving chemotherapy there 
were 10 relapses (3*2 per cent.). The standard error of the difference 
i s  ± 1.76 so that the difference, is  just significant. I f  the cases 
are subdivided into the stages of the experiment, however, we find 
the following state of affairs (Table 13)*
TABLE 13.
The Occurrence of Relapse in Erysipelas; The Effect . 
of different methods of treatment thereon.
Chemotherapy. Ultra.-violet 
Light.
. Stage 1 8 (7*$) 8 (7-7^)
Stage 2 2 (1 . 36) 10 (7 -4 «
Stage 4 0 (0%) 3  (*. SO
Note: In Stage 1 treatment was confined to the acute stage.
In Stages 2 and 4 treatment continued into 
convalescente.
In /
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In the first stage the incidence in the two treatment groups 
is  similar, whereas there is  thereafter a decided fall in the 
incidence in those cases receiving chemotherapy. Thus, in 206 
cases given larger initial dosage and receiving the drug for 10- 1 2 - 
days after cure of the local lesion, the relapse rate is  0*97 per cent., 
whereas in, 202 cases given ultra-violet light, during the same time- 
interval, the rate i§  6.45 per cent.- The conclusion seems justified 
that i f  relapse is  to be prevented, chemotherapy must be continued 
for a period after apparent recovery.
4. Deaths.
No information as to the efficacy of chemotherapy in regard to the 
reduction of mortality can be deduced from the fatality rates of the 
present series of cases. After the first stage of the experiment 
any case which appeared very i l l  received sulphonamides, so that, i f  the 
drugs were life-saving, ell the cases most likely to succumb received 
the drug at some time. Among the 6l 8 cases there were 19 deaths, giving 
a fatality rate over all of about 3*1 Per cent. With ultra-violet 
light the fatality rate was 3*26 per cent.; with chemotherapy the
rate was 2.87 per cent. For cases treated in hospital these are low 
figures for a fatality rate, which has in the past ten years usually 
fluctuated around 7 -1 0  per cent., and serve to emphasise how 
unsatisfactory the fatality rate is  as a factor of assessment.
5. The Duration, in days, of Residence in Hospital.
Table 14 shows the frequency distribution of the period in hospital
for both methods of treatment. For convenience the cases have been 
arranged in weeks. The mean days residence for those cases receiving 
ultra-violet light was 17«l6 days; for the cases receiving chemotherapy
/
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chemo therapy the mean was 15.34 days. The difference between the
two averages is  not statistically significant.
*
TABLE 14.
Duration of Stay in Hospital.
Days
Treatment -7 -14 -21 -28 -35 -42 -49 -56 57 + Total
Chemo­
therapy. 9
.  -
195 72 15 10 4 0 2 4
t  >■; 
311
Ultra­
violet
Light. 9 155 90 22 6 11 4 3 3
•J*
333 ‘
Combined 18 350 162 37 16 15 4 5 7 614
v/
Note: 3 cases omitted: Duration not noted.
•j-
1 case omitted: Duration not noted.
4
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TABLE 15.
Summary of Results.
Comparison o f  Chemotherapy and Ultra-Violet Light*
Chemo­ Ultra-violet Difference
(S.E.D.)Factor of Assessment therapy (per cent.)
Light.
(per cent.)
1. Ceased spread after 
24 hours in hospital 90.1 54 10.9
2. Apyrexial after 48 
hours in hospital 81.7 49.4 9.0
3* Toxaemia absent after 
72 hours in hospital 80.7 55.4 7.0
4. Complicated Case Rate 
(true infective 
complications) 11.6 I8.3 2.4
5. Nephritis - 2.6 2.9
6. Relapse Rate 3-2 6.9 2.1
7. Fatality Rate 2.9 3*3 -
8. Average Days Residence 15.34 17.16 -
Total number of Cases 312 3)6
(In the last column is  shown for each factor of assessment the ratio of 
the percentage difference to the Standard Error of the Difference 
(S.E.D.)).
Table 15 summarises the results of the comparison of the two methods 
of treatment; the accumulated experience shows consistent benefit 
from chemotherapy* The results may be summarised under the following five 
headings: -
(1) The improved effect of sulphonamides is  most obvious in cutting 
short the duration of spread, primary pyrexia and toxaamia.
(2) The complicated case rate shows a slight reduction hit 
suppurative complications are not eradicated,
(3) The drugs used can have l i t t le  deleterious effect on the kidneys 
and may reduce the incidence of nephritis.
(4) The relapse rate is  only reduced i f  chemotherapy is  continued 
into convalescence.
(5) There may be a slight reduction in the number of deaths and in the 
duration of the patient1 s residence in hospital.
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APPENDIX I .
TABLE 1.
The Distribution of certain Characteristics 
in 5L2 Cases of Erysipelas*
CHEMOTHERAPY.
Age
Group
(Years)
M8le Female Site,
etc.
Male Female
0-5 9 15 Face 125 103
Head 16 9 •
6-10 2 3 Trunk 3 8
Arm 3 6
Leg 6 33
-20 12 22
Primary 122 122
-3> 13 21 Recurrent 31- 37
-40 28 20 Ideo
pathic
-50 32 33 Primary 79 8o
-60 29 28 Recurrent 27 23 *■
-70 19 12 SurgicalPrimaiy 42 41
Recurrent 3 * 14Over 70 9 5
Associate
Total 153 159
ed
Disease 26 26
* 1  case in each not noted.
In these and subsequent tables:
Primary = an original attach of erysipelas.
Recurrent = an attack; of erysipelas not the first from
which the patient had suffered.
Idiopathic = a case where there was no obvious focus of
entry in the skin. 1
Surgical = a case where the focus of entry was discernible.
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APPENDIX I.
TABLE 2.
The Duration, in days, of illness prior to admission. 
CHEMOTHERAPY*
Days
Sex 0 1 2 3 4 5 over 5 Totals
M 8 42 41 26 18 10 8 153
F ‘ 8 49 53 28 11 3 7 159
TABLE 3.
The Distribution of certain Characteristics 
in gP6 cases of Erysipelas^
ULTRA-VIOLET LIGHT.
Age
Group
(Years)
MaLe Female Site,
etc.
. Male Female
0-5 8 9 Face 125 • 109
Head 18 14
6-10 3 1 Trunk 2 . 3
Arm - 3
-20 10 21 Leg | 7 25
Primary I 20 -^~ I I 9 --------
-30 12 27 Recurrent 32 35
-40 21 30 IdiopathicPrimary 81* 74
-50 36 32 - Recurrent 25 25
-6o 30 20 SurgicalPrimary 37* 45
-70 25 11 Recurrent 7 10
over 70 7 3 Associated
Disease 30 26
Total 152 154
* ’ 2 cases not noted.
APPENDIX I.
TABLE 4.
The Duration, in Days, of illness prior to Admission.
ULTRA-VIOLET LIGHT.
Days
Sex 0 1 2 3 4 5 over 5 Totals
M 4 42 43 23 17 5 13 152
F 8 47 49 21 14 7 8 154
Snodgrass,
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CHAPTER V.
Part 2.
The Effect of the Sulphonamides upon Erysipelas in
Infants and loung Children.
Tfihen the severity of erysipelas at different age groups was 
discussed (Chapter II) attention was drawn to the high mortality under 
the age of five years* An analysis of the results in those cases under 
five years of age which received sulphonamides has, therefore, undoubted 
value* A total of 100 cases in this age group received treatment with 
some form of sulphonamide. Reference has already been made to the 
exclusion of many of these cases from the later stages of the investigation*
A preliminary study of the age and sex distribution in this selected 
age-group, (Appendix 2, Table 1) shows a fairly even division between the 
two sexesj in both, the first year of l i fe  shows the highest incidence 
(males, 63 per cent, and females 61 per cent.). As one would expect, the 
great majority of the attacks at this period of li fe  are primary. (The 
four exceptions, although classed as recurrent cases, were admitted with
a second attack which had closely followed a primary attack about one
/
week earlier). In a rather high proportion of the cases in both sexes 
a lesion of the dcin was thought to bear a causal relationship to the 
erysipelas.
The "surgical" lesions responsible for the onset of the erysipelas 
are analysed belo^ r.
Causative Factor in Cases of "Surgical” Erysipelas (0-5 yrs).
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Skin sores, abrasions, accidental c u ts  24 cases
Incision of abscesses * ••*••••••• .10 "
Infection of burns  ........... ••• 4 "
Umbilical infections . . . .   4 "
Impetigo  ...............    4 "
Infection following circumcision  ............  3 ®
Retropharyngeal Abscess   2 "
Infection of Naevus.........................    2 "
Operation for Mastoiditis...................................... 1 "
Chronic Otitis Media * 1 "
Ruptured Spina Bifida     1 "
Post-vaccinal infection 1 "
Causative lesion not noted     6 "
6 3  cases
The l i s t  shows a very varied etiological factor. (The rarity of 
post-vaccinal infections!s striking and interesting. Tht»$ they should, 
today, be bracketed in uncommonness with ruptured spina bifida speaks 
for the great improvement that has been made in the aseptic conduct of 
the operation, when one remembers that the occurrence of suppuration and 
erysipelas used to be a strong argument of the anti-vaccinator) •
The 100 cases to be reviewed received different forms of chemotherapy 
These were:-
Sulphanil amide............... .. ............. .. 71 cases
Sulphonami do-chry soi dine . . . . . . . . .  13 ”
Ben zyl-sulphanil amide 10 n
Sulp hon ami do- chry soi din e 
combined with Ultra-violet 
Light ...................................................... 6 "
Total : 100 cases
Record of Results.
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1. Duration, in days, of Spread, Primary Pyrexia and Toxaemia.
TabLe 16 shows the duration in days of spread, pyrexia and 
toxaemia.
TABLE 16.
The Duration, in Days, of Spread, Pyrexia snd 
Toxaemia in Cases 0-5 Tears of Age.
Days
Characteri s ti c 0 l 2 3 4 5 6 7 over7 Totals
Spread 45 47 8 0 0 0 0 0 0 100
Pyrexia 3 29 46 l i 5 1 0 i 4 100
Toxaemia 3 0 20 39 22 7 3 2 4 100
.—  - I , .  . . —
Summary:
Proportion of cases showing no spread after 24 hours 
in hospital...........................................................................  $2 per cent.
Proportion of cases showing absence of fever after 
48 hours in hospital  78 per cent.
Proportion of cases showing absence of toxaemia
after 72 hours in hospital,........... .................................  62 per cent.
There is  no control group with which these figures can be compared. The
x disease is  particularly severe in this age-group. Comparison of these
figures with those given in the earlier analysis when, for all ages,
chemotherapy was compared with the effect of ultra-violet light, shows
that there is  li t t le  difference between them. For all ages, we found no
spread after 24 hours in 90*1 per cent., no fever after 48 hours in 81*7
per cent., and no toxaemia after 72 hours in 80*7 per cent. The striking
similarity of the figures for the duration of spread indicates that
sulphonamid.es are no less effective in controlling the disease in this
selected age-group in which the disease is  known to be severe. As one might \ '
expect, however, toxaemia abates rather more slowly. The figures are given 
in the form of a cumulative frequency distribution in Figure 6.
2. The Incidence of Complications.
The following complications were encountered (Table 17)* (It may be 
noted that in this age-group the absence of accompanying diseases or 
degenerations has resulted in all the complications falling into the
third group, viz. those due to the erysipelas itse lf) .
TABLE 17*
The Compl ications of Erysipelas encovintered in 
Age-Group 0-5 Years.
r 65 -
Compli cation Number
Suppurative conditions, subcutaneous and
gland abscesses, etc. .......................... .. 16
Pneumonia ................................ ................. 5
Otitis Media ............................................ 3
Non-suppurative adenitis .................... l
Streptococcal meningitis 2
ToxLc Convulsions .................................. 2
To tal Compli cation s .............. ........... .. 29
£.
T UL  D U R A T I O N  IN DAYS OF S P R E A D ,  P R IM A R Y  
P Y R E X I A  CTO X A E M I A
(  O S  YLS )
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The number of complicated cases was 26 and these showed 29 individual 
complications. The incidence of complicated cases (26 per cent.) in 
this age-group is , as one would expect, high; for all ages, only 11.6 
per cent, of cases showed a complication directly due to the erysipelas.
It  will be remembered that the diminution of septic complications in those 
cases treated chemically was not striking and the figures in this selected 
group of cases seem again to emphasise that the use of sulphonamides by 
no means eradicates the possibility of septic complications.
No case showed nephritis or other renal complication.^
3* The Incidence of Relapse.
Seven cases showed relapse in hospital. All but one of these occurred 
in the early stages of the experiment when the drugs were administered only 
during the first few days of the infection. In this one exception 
a relapse developed after the incision of numerous subcutaneous abscesses. 
Among 48 cases which received sulphanilamide throughout the whole of 
their period in hospital, no relapses were noted.
4. Deaths.
* There were ten deaths, giving a fatality rate of 10 per cent. Eight 
of these deaths occurred under the age of one year; the other two were 
between one and two years. In four cases the ages were 5 days, 12 days
and 14 days (2 cases). The causes of death were:-
Bronchopneumonia (2 cases).
Marasmus (2 cases, both 14 days old).
Large sacral abscess with enteritis.
Streptococcal ^meningitis with pneumonia.
Streptococcal meningitis.
Aspiration pneumonia.
Ruptured spina bifida (5 days old).
Large abscess of txittock (12 days old).
It /
-  67 -
I t  is  perhaps permissible in this group to u tilise  previous fatality  
rates as a comparison owing to the high rate which prevailed in past 
experience. During the years 19^3-1935 the hospital admitted 353 cases 
under 5 years and of this number 76 cases died, giving a fatality rate 
of 2L.53 Per cent. The fatality rate in the present series is  10 per 
cent. As the difference (11*53 Per cent.) is  three times its  standard 
error ( ±3*7) i t  may be regarded as statistically significant.
Further subdivision shows that of the 62 cases under one year in the 
chemotherapy group 8 died (fatality rate 12.9 P©r cent.). During the 
period 1928- 1935* 176 cases under the age of one year were admitted.
Of this number, 62 died; a fatality rate of 35*4 Per cent. The difference 
(22.5 per cent.) has a standard error of ±5*6* there is  l i t t le  doubt 
that the difference is  statistically significant.
5. Days Residence in Hospital.
The mean days residence in hospital was 16.6 days, the figures 
ranging from a minimum of 3 to a maximum of 84. An average stay 
in hospital of li t t le  over a fortnight must be considered as 
satisfactory for an age-group which previously bore a fatality rate 
of over 20 per cent.
SUMMARY.
The analysis of a series of cases under the age of five years (in 
which age-group the disease is  known to be particularly severe) shows 
that chemotherapy produces rapid cessation of the characteristics 
of the acute stage of the disease — namely, spread, pyrexia and 
toxaemia.
There is  l i t t le  essential difference in the rapidity of 
disappearance of these factors between the cases under five 
years and the total cases at all age-groups, who were given 
some form of sulphonamide.
There is  a rather high incidence of complications directly 
attributable to the erysipelatous lesion in this selected 
age-group.
Relapse is  uncommon when cases receive the drug during the 
period of convalescence.
The fatality rate of 10 per cent, is  a marked reduction on that 
found among cases of similar ages (0-5 years) during the period 
1928-1935 inclusive. JUrther, the fatality rate under one year 
is  12.9 per cent.— less than a half of that prevailing in pre- 
sulphonamide days.
APPENDIX 2.
TABLE-1.
Distribution of 100 cases aged 0-5 years, showing Age, Sex, 
Type and Site of Erysipelas.
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Male, Female.
0-1 34 28
1-2 7 7
Age 2-3 6 5
Group > 4 4 2
4-5 3 4
Totals 54 46
Primary attack ........................ 52 44
Recurrent attack .................... 2 2
Totals 54 46
Idiopathic ................................ 20 17
Surgical 34 29
Totals 54 46
{Face 27 11Site (Face and Head 5 5
(Head 4 4
Affected (Trunk 7 7
(Arm 2 3
(Leg 9 16
Totals 54 . 46
CHAPTER V.
Part 3*
The Effect of the Sulphonamides upon Cases admitted 
early in the Disease*
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The value of the drugs in curing the disease may be tested in a
third way — namely, by analysing the results obtained with them in
cases admitted to hospital on their first day of illness*
In such cases one might reasonably suppose that the disease is  in
an active phase of spread, and that the patient himself has not yet
had time in which to’ gather together those protectivesubstances which -
might effect natural cure and which might therefore be adjuvant to
treatment by chemicals. Of the total 1,277 cases, ^4 were admitted on
their first day of illness and were given some form of sulphonamide.
The actual numbers treated in the different ways were:-
Sulphonami do-chry soi dine and Ultra-violet Light •••••• 3 cases
Sulphonami do-chry soi dine  ...........   ..12  n
Sulphanil amide       2 6 n
Benzyl-sulphanilamide  .........    9 ”
Carboxy-sulphonamido-chrysoidine............................... ............4 n
Totals .«• *. 5  ^ cases
The age and sex distribution of this group is'shown in Appendix 
3, Table 1.
Record of Results.
1. Duration, in days, of Spread. Primary Pyrexia and Toxaemia.
TABLE 18.
Duration, in days, of Spread, Pyrexia and 
Toxaemia in those cases admitted on 
First Day of Illness.
Days
0 1 2 3 4 5 6 7 over7
Spread 23 a 9 l 0 0 0 0 0
Pyrexia 2
\ 13 29 6 3 1 0 0 .  0
Toxaemia 1 8 8 20 15 1 1 0 0
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Summary:
Proportion showing no spread after 24 hours 
in hospital ....................................................
Proportion showing no pyrexia after 48 hours 
in hospital .................................................• •
s
81.4 per cent.
81.4 per cent.
Proportion showing no toxaemia after 72 
hours ini hospital .................................... y< 68.5 per cent.
Table 18 shows the results obtained in respect of the duration, in 
days, of spread, pyrexia and toxaemia. The summary of the table shows a 
rapid cessation of each factor. Here again there is  no direct control 
series. (The number of cases acinitted to the wards on their first day 
of illness and assigned to control methods of treatment was only 18).
Again, however, there is  value in comparing these figures with the 
equivalent proportions obtained with chemotherapy in the preliminary 
analysis, namely, 90*1 per cent., 81.7 per cent, and 80.7 per cent, respect­
ively. I t  is  interesting that spread seems to continue slightly longer 
and toxaemia to abate more slowly in those cases beginning therapy on 
their first day of illness. One may imagine, however, that this group 
contains a greater proportion of acute actively-spreading cases. A 
slightly slower effect might therefore be expected. The difference is  
slight and the conclusion seems justified that therapy is  effective.
In addition, clinical support is  given to the belief that the action of 
the drugs is  directly anti-bacterisl, for, had the action been of an
antitoxic nature, one might have' expected that cases which received 
treatment so early would have shown a more rapid cessation of toxaemia 
than that which occurred in cases treated later in the disease.
2. /
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2. Incidence of Complications.
Seven complicated cases were encountered. In one of these the 
complication was present on admission and consisted of transient 
glycosuria which cleared up in a few days. The other complications 
noted weres-
Aspiration pneumonia 1 case
Acute Otitis Media •••••••........................1 case
Suppurative cervical adenitis .•••••. 1 case
Subcutaneous Abscess   2 cases
Acute bronchitis..................... ••••••••• 1 case.
The complicated case rate (of complications directly attributable to the 
erysipelatous lesion) is , therefore, 11.1 per cent. This figure may be 
compared with that obtained with chemotherapy in the control series 
proper, namely 11.6 per cent. The close similarity of the two figures
is  interesting. Theoretically one would presume that cases admitted so
early In the disease should be less liable to septic complications, since 
i t  is  unlikely that, in such a group, the complications have already begun 
to appear before therapy is  started. The preliminary analysis of the 
cases in Part 1 of this chapter suggested that the sulphonamides had not 
produced a spectacular reduction in the incidence of septic complications, 
and the complicated case rate in this present group serves to emphasise 
this fact.
3* The Incidence of Relapse.
No case was observed to relapse.
4. Deaths.
There were three deaths. In none of these could the failure of
treatment be entirely blamed. One was a child of five days old with a
ruptured spina bifida; another, a child of one year who had a retro­
pharyngeal abscess and erysipelas of the fauces spreading on to the face, 
and /
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and in whom death followed the development of an aspiration pneumonia; 
the third patient was over seventy years of age and had an advanced 
epithelioma of the right ear into which, before admission, radium needles 
had been inserted* For what i t  is  worth, the fatality rate is  5*5 Per cent. 
5* Days Residence in Hospital*
The mean duration, in days, of residence in hospital was 13*!»  
maximum 3^ 5 end minimum 2 days. The distribution was:-
0-10 days -  14 cases
11-20 « -  34 "
21-30 " — 5 "
31-40 n -  1 case.
/
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SUMMARY.
(1) In a group of cases receiving chemotherapy with sulphonamides from 
the first day of their illness, the duration of spread, pyrexia 
and toxaemia was slightly longer then that found in a group
of cases admitted at all stages of the disease. It  is  
suggested that this slower effect may be due to the presence  ^
in such a group, of patients more acutely i l l  and the omission 
of patients (admitted late) in whom the lesion was already 
subsiding.
i
(2) The complicated case rate showed l i t t le  difference from that 
found in cases admitted at all stages of the infection.
(3) No conclusions can be drawn from the fatality rate.
(4) The mean days residence was slightly shorter than that of the 
group of cases admitted at all stages of the infection.
v
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APPENDIX 3.
TABLE 1.
Age end Sex Distribution o f 54 Cases o f  Erysipelas admitted 
on their F irst Day o f  I lln ess .
Male. Female.
o-5 12 2
6-10 3 1
-20 l 3
-30 l 5
-40 0 2
-50 4 3
-60 7 1
-70 1 3
over 70 2 3
33- 23
CHAPTER V.
Part 4.
A Study of a Group pf Cases which in itia lly 
received no specific treatment.
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It  is  convenient at this point to describe the results obtained 
when the attempt was made to give no specific treatment (see Chapter II). 
I t  will be recalled that s.t one stage an experiment was run where every 
third case admitted to hospital received powders which contained sugar 
of milk. As a precaution against harm occurring to the patients, each 
case was reviewed at twelve, twenty-four and forty-eight hours after 
admission; i f  i t  was thought then that harm might result from further 
delay, therapy with sulphanilamide was instituted immediately. The 
cases were a random selection} even an apparently severe case was 
included initially in the "no treatment" group. No case under the 
age of five years was included.
The data shown in Appendix 4 indicate that the cases were a 
fair sample of the ordinary admissions; each age-group over five 
years was represented; all sites were represented; and a fair 
proportion of the cases were admitted early in the disease and were 
classified as moderate or severe. The results of treatment in 
respect of the duration of spread, pyrexia and toxaemia are shown ‘ 
in Table 19*
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TABLE 19.
Cases "allotted to N^o Treatment" Group: Results in respect
of duration, in days, of spread, pyrexia and toxaemia.
■ Duration, in days, cessation.
until .
0 1 2 3 4 5 6 7 over7
SPREAD
Completed
course 13 10 6 2 0 0 0 0 0 3
Failed:
given Sulphanilamide. 1 5 14 12 3 0 0 0 0 35
PIKBHA
Completed
course 5 10 9 4 1 1 0 1 0 3
Failed:
given Sulphanil amide. 0 '2 12 12 6 1 1 0 1 35
TOXAEMIA
Completed
course 2 3 7 8 11 0 0 0 0 3-
Failed:
given Sulphanil amide. 0 0 6
- J
2 11 8 7
—
1 0 35
I
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A human experiment of this kind has, of course, its  limitations; 
and the fact that certain cases had within twenty-four hours of 
admission to be assessed as "failures" and given sulphonamide ma^ es 
i t  hard to analyse the results. The following points stand out, however. 
Almost half of the cases were permitted to complete their courses; 
and in this group no less than twenty-three cases ceased to spread 
within twenty-four hours of admission. It  will at once be said 
that these were but the mild cases in which the disease-process 
had spent itse lf prior to admission. Certain clinical features 
of the thirty-one cases which completed the course and of the 
twenty-three cases which ceased to spread within twenty-four hours 
of admission are shown in Tables 20 and 21.
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TABLE 20.
Clinical Details of XI Cases which completed
"No Treatment" Course. \
Clinical
Classification
Mild 10
Moderate 20
Severe 1
T<aaperfiture on Admission
-99
10
-100
8
-101
4
-102
6
-103
3
103 + 
0
Days i l l  prior to Admission
0 1 2 3 4 5 over 5
3 10 9 4 3 l 1
TABLE 21.
Clinical Details of 25 Cases which completed "No 
Treatment" Course and showed no spread after 
24 hours in hospital.
Clinical
Classification
Mild 7
Moderate 15
Severe l
Temper*ature on Adiaission
-99
9
-100
6
-101
3
-102
4
-  103 
1
Days i l l  prior to Admission
0 1 2 3 .4 5 over
5
2 7 6 3 3 l 1
I t  will be seen from the tables that in both groups a fair proportion 
was classified by me (in the same manner as was used for all* cases 
throughout the whole therapeutic tria l), as moderately i l l ;  one, common 
to both ta-bles, being regarded as severely i l l .  Many showed a high 
temperature; and in many cases the illness had just begun.
I do not want to overdraw the picture as regards their severity.
That i 6 not at all necessary. The cases have served a useful purpose
in showing how difficult i t  is  to forecast the outcome of a case of
erysipelas; and in demonstrating very convincingly that, of the average
cases which secure admission to hospital, about half would show spontaneous
cure within four to seven days, and no less than one-third might be
expected to show no further spread after a period of twenty-four hours
under any form of treatment. It  also suggests that when carrying out
a therapeutic experiment in this disease there is  a very real danger ,
in "choosing" cases, on grounds of supposed severity. Clearly, i t  is
best to submit all patients, irrespective of their clinical classification,
to the therapeutic trial. The finding has this further value: i t  serves
to focus more sharply the apparently startling success of sulphonamides
in this disease. Ihen we now refer to the 80 or 90 per cent, of cases
which cease to spread within twenty-four hours of commencing treatment,
we must remember that the first thirty per cent, of that figure should be
mentally subtracted to allow for the proportion which would in any case have *
ceased to spread within that period, finally, i t  serves to illustrate
just how effective was the treatment upon which we relied prior to the
introduction of chemotherapy; my own results with ultra-violet light, which
caused cessation of spread within twenty-four hours of admission in $4 per
cent, of cases, would suggest that this method of treatment was of some 
limited benefit.
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TABLE I . ,
Clinical details of 66 Cases of Erysipelas which were admitted 
to the "No Treatment" Group.
APPENDIX 4.
Age
Group
(Years)
Male Female Site
etc.
Severity Grouping
6-10 0 1 Face and Head 48
11-20
-^0
3
6
6
6
Trunk 2 Mild. 17
-40 5 8 Arm 4 Moderate 44
-50
-60
5
8
6
3 i 
t-1 j S 1 i i i i i i i __i
__
_ 12
Severe 5
-70 5 2 Totals 66
66
?l + l 1 lype;
Totals
Primary Cases 47
Totals 33 33
Recurrent Cases 19
Totals 66
TABLE 2.
Duration, in Days, of illness prior to Admission*
0 1 2 3 4 5 over 5
4 18 24 9 8 l 2
Part 5.
An Examination of the Consistency of the 
Results — including a Survey of the
CHAPTER V.
Fatal Cases.
-  82 -
Finally, an effective therapeutic measure, should produce consistently 
good results. In other words, unless a marked change occurs in the 
character of the disease treated, the results from year to yeai* should 
show dose similarity. Further than that, even although I have insisted 
that slight changes noted in hospital fatality rates must be regarded 
with suspicion, the introduction of an effective method of treatment 
Should result in a lowering of the general mortality in the country 
from the disease. This is  especially true i f  the administration of the
new treatment is  simple and can be efficiently carried out in general\
practice. • (It is  undoubtedly one of the great advantages of the 
sulphonamides that their administration calls for no special sk ill).
In this present section, therefore, I shall try to show first that the 
results which I have obtained with sulphonamides show great consistency 
from year to year, and, second, that consequent upon their introduction 
a decided drop in the death rate from erysipdas has occurred.
A. Consistent Effect of the Sulphonamides 
over three and a half years.
Reference to the table at the beginning of this chapter (Table 8) 
shows that during the period 193&-1939 a grand total of 787 cases of 
erysipelas were treated with different chemottherapeutic substances.
The different drugs used, the year in which they were used, and the 
number of cases treated are shown in Table 22. It  must be understood 
that the subdivision into years in Table 22 is  by no means dear-cut;
1936 spreads over into 1937* 1937 into I 938, and so on. No great /
great disadvantage arises from this fact. In effect, the four successive 
periods of time cover the years from June I936 until December 1939* Tk© 
only reason for keeping the groups under their particular treatment is  
that to divide them into exact calendar years would present considerable 
difficulty without serving any additional useful purpose.
There is  only one respect in which the subdivision is  unfair. It  
has already been pointed out that after the two preliminary tria ls ' 
of the drugs in 193  ^ ©ud- the beginning of 1937> ©11 children under the 
age of five years received sulphanilamide. 1% have thought i t  simplest 
merely to exclude this group of 70 children from the present analysis. 
They were treated during late 1937* 193^ ©ud 1939> ©ud to .subdivide 
them into these years would be difficult. It  must therefore be 
borne in mind that, although the 1936-1937 cases include the age- 
group 0-5 years, from the figures for 193  ^ and 1939 i t  is  excluded.
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TABLE 22.
The different chemotherapeutic drugs used, 1936-1939*
Tear Drug Used. No. of Cases. Total
1936
1937
Sulp hon ami do- chry soi din e 106 106
Sulphonamido-chrysoidine + 
Ultra-Violet L ight..................
p-amino-benzeae- 
sulphonamide • •.................... ..«
54
135 189
1933
Sulphon ami do- chry soi din e
p-amino-benzene-
sulp hon amide..............................
60
122
p-ben zyl-amino-ben zene- 
sulphonamide ............................. 60 242
1939
Sulp hon ami do-chry soi din e 
Sulp hon ami do-chry soi di n e
71
90
Carbo xy-sulphonami do- 
chrysoidine........ J 9 250
787 787
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TABLE 23»
t
Summarised Results of Treatment with Sulphonamides ' 
over a three and a half Year Period,
1936 1937 1933 1939 Combined
Characteristic Total
Cases
106
Total
Cases
189
Total
Cases
242
Total
Cases
250
Results
in 787
Cases.
Number of cases ceasing 
to spread after 24 hrs, 
in ho spi tal .................
86
(81.1)
175
(92.5)
200
(82.5)
209
(83. 8)
670
(85)
Number of cases 
apyrexial after 48 hrs, 
in ho spital
85
(30.3)
145
(76. 8)
176
(73-3)
219
(87-5)
627
(79-6)
Number of cases 
becoming non-toxic 
after 72 hrs, in 
hospital .............. ..»•
86
(81. 1)
144
(76. 2)
128
(52.9)
197
(78. 8)
555
(70.5)
Number of cases 
showing a complication 
directly due to the 
erysipelas ..................
16
(15- 2)
27
(14. 3)
20
(8.3)
24
(9-6)
87
(11.01)
Number of cases 
showing relapse , ,  •.,
8
(7.6)
4 ’ 
(2. 1) (0.4) (0.4)
14
(1 . 78)
Fatality rate 
per cent.
4
(3.8)
6
(3-2)
5
( 2.06)
2
(0.8)
17
(2.15)
*
Note: The figures in parenthesis are percentages of the total in
the group.
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The actual results obtained in the four groups of cases are shown 
in Appendix 5, Tables 1 ,2 ,3  831 ^  4. In order to simplify comparison, the
figures are summarised in Table 23* It  is  to be remembered that during 
the three and a half years, four different sulphonamide drugs were used; 
and that the dosage in which they were given varied widely. The dose 
similarity that is  to be noted between the equivalent percentages is , 
therefore, all the more surprising, and where differences do exist 
reasons can he readily advanced.
(a) During 1937, the rate of cessation of spread is  more rapid than 
in any other year. Reference to the appropriate table shows that during 
this period the majority of the cases received £-amino-benzene-sulphonamide. 
The figures, therefore, might suggest the possibility that the radide 
achieves more rapid cessation of spread than do the red dyes.
(b) During 193^, toxaemia appears to have abated more slowly.
During this period the drugs were tested with a view to ascertaining 
the optimum dosage of the drugs. Many cases were treated with what one 
would now regard as an excessive dose. The low figure in 193  ^ suggests 
the possibility that, with high dosage, toxaemia may be prolonged. This 
possibility will be more fully discussed.
(c) When the complicated case rates for 193^ 3-937 are compared
with those for 19Z0 and 1939, i t  will be observed that the latter show a 
marked fa ll. In the earlier discussion of the results of treatment with 
sulphoharaides in the age-group 0-5 years, i t  was noted that the complicated 
case rate in children was higher than in adults. It  is  probable that
the exclusion of children from the 193  ^ and 1939 cases supplies the 
reason for the low complicated case rates in these years.
(d) /
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(d) A marked diminution in the number of relapses occurring during 
the period in hospital is  recorded. The change did not occur suddenly, 
although similar low rates are recorded for 19Z$ 1939* It  will be
recalled that to begin with the sulphonamides were stopped after the 
apparent cure of the acute stage of the disease and that only in the 
last two years were the drugs administered continuously during 
convalescence. The figures add further weight to the suggestion already 
made that such a method of administration is  essential i f  relapse is  
to be avoided; and i t  is  interesting to record that the two relapses 
that did occur in 193$ and 1939 both occurred in cases in which the 
administration of the drugs had’ been terminated.
This survey of the consistency of therapeutic effect may be 
concluded by giving, briefly, the collected results of the treatment 
of the acute stage in those cases over the age of five years who 
recovered (Table 24). (The results under the age of five have 
already been recounted. Deaths may be omitted since all deaths 
will be described in the subsequent section).
TABLE 24.
Duration. In Days. of Spread in 742 Cases receiving some 
form of Sulp hon amide (Recoveries only).
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Duration in Days
0 l 2 3 4
fo ta ls
Males 215 123 34 5 1 37®
Females - 140 152 66 5 1 364
Totals 355
(47.9)
275
(37.1)
100
(13. 5)
10
(1.3)
2
(0.3)
742
Note: The figures in brackets are percentages of the line total.
Three points in this table may be stressed* First, the series is  
a large one snd contains all the cases admitted to hospital over a 
period of several years who were given some form of sulphonamide.
Second, i t  shows that 85 per cent* of these cases ceased to spread 
within 24 hours of admission. Third, and a point of great value, i t  
shows that in only 1.6 per cent, did spread continue for longer than 
forty-eight hours. This last figure is , in my opinion, the most telling
one; had the table shown a long, dwindling "ta il” extending out until 
the seventh or eighth hospital day, one might have suspected that, by 
some chance, a large number of mild cases had been included. The cases 
received sulphonamide entirely by random selection, they were admitted 
over an extended period and are a representative sample of the disease 
as i t  occurs in the City; i t  may be assumed that they include a 
considerable number of severe cases. That all should have ceased to
spread within four days of admission to hospital is  striking evidence 
of beneficial treatment.
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Table 25 shows the duration, in days, of primary pyrexia in 
this group of 742 cases.
TABLE 25. .
Duration, in days, of Primary Pyrexia in 742 cases of erysipelas 
who received some form of Sulphonamide (Recoveries only).
Duration in Days
Total0 1 2 3 4 5 6 7 over 7
Males
Females
26
15
153
124
146
129
37
59
8
22
.. . ..j
5 3
3
0
1
r 
11
0 
1 m111
378
364
Total 41 277 275 96 3^ 13 6 1 3 742
(a) ( 5- 5) (37.4) ( 37.1) 03.0) (4.1) (1.8) (0.8) (0.1) (0.4)
(b) (29. 6) (39.3 ) (13.9) (4. 3) (1 . 9) (0. 9) (0.1) (0.4)
(The figures in brackets are percentages of the line total, (a) including 
apyrexial cases and (b) excluding apyrexial cases).
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Table 25 shows that 80 per cent, of all cases admitted were 
apyrexial after forty-eight hours in hospital; i f  cases admitted without 
fever are excluded, the proportion is  78*9 P©r cent. Again, only 7*2 
per cent, of the cases continued to show a pyrexia after three days in 
hospital; omitting apyrexial cases, the proportion is  7*6 per cent.
From the point of view of the person who treats a case of erysipelas 
only occasionally, these are important figures. Erysipelas is  one of 
the few diseases in which the progress of the disease can be seen. From 
the results in this large series of cases one may almost say that i f  a 
suspected case of erysipelas does not cease to spread within 24 hours
after beginning sulphonamide therapy, then the diagnosis should be
reviewed. In one group of cases, my own clinical experience suggests that 
such a ruling may be of value. The initial efflorescence of a case 
of cavernous sinus thrombosis is  very frequently mistaken for erysipelas. 
In a number of cases of this type seen, both in the hospital and in 
consultation, the lack of response to sulphonamides has often helped an 
earlier diagnosis.
B. The Effect of the Sulphonamides upon the
Mortality from Erysipelas.
The fatality rates experienced during the four-year period were
recorded in Table 23. The rates for 1933 and 1939 are tfcielo west that
have ever been recorded for cases treated in Ruchill Hospital. When 
they are compared with the fatality rates experienced in this hospital 
during past years, there is  no doubt that some change has occurred. The 
suggestion, however, might be made that the introduction of sulphonamides 
coincided with a reduction in the severity of streptococcal infections, 
and that much of the apparent benefit of the new drugs is  due to this /
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this fact. For such a change to have occurred would not, indeed, be 
impossible; i t  is  well known that the virulence of the streptococcus 
has waxed and waned in the past. I t  would, however, be surprising for 
such a change in the character of a disease to occur so suddenly. 
Nevertheless, the criticism must be met. For this purpose the recorded 
mortality rates per 1,000 registered cases for Glasgow as a whole, 8nd 
for England and Wales, during the past ^0 years are worth further study. 
The figures were already presented in Chapter II ; and this graph is  
now repeated (Fig. 7)*
Study of Fig. 7 shows, as one might expect, that in the 
comparatively small Glasgow series, the death rate per thousand 
registered cases has varied considerably. From 1911-1921 the rate rose 
from 37 to 66 in an unsteady fashion, falling sharply again in 1927 to the 
level of 34* In 1932 a peak was again reached of 57 deaths per 
thousand cases and although the rates for 1933* 1934 and 1935 were 
lower (56, 51 54 respectively), they gave no hint of the spectacular
fa ll that occurred in subsequent years; a fa ll which, in 1939* reached 
the lowest level recorded of 17 deaths per thousand cases. Sulphonamides 
were first used in Glasgow by me in 193^ the trend of the graph 
suggests that there is  a relationship of cause and effect between their 
introduction and the subsequent fa ll. The curve of the English figures 
shown in the same graph suggests even more strikingly a similar
I
conclusion. Here i t  is  abundantly clear that the severity of erysipelas 
steadily increased from I 9H  to reach a peak in 1934* The rates for 
1935 s11^  1936 sh°w a slight reduction on that for 1934 but are in
fact s till well above those observed in the previous twenty years. It 
can be appreciated that a drug which was in its  experimental phase in /
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in 1936 would have only a limited application in that year in general 
practice and i t  is  therefore not surprising that the fa ll in the case- 
mortality rate should begin somewhat later in England than in Glasgow. 
Since 1936, however, the rate has decreased rapidly so that in 1940 we 
find, in England and Wales as in Glasgow, that the death rate is  the 
lowest on record, namely 16.2 per 1,000.
C. The Mortality in the Present Series.
The analysis of the material under observation may be concluded by 
describing the deaths among those who were treated originally with 
sulphonamides. The total number of cases treated with one of these 
drugs was 8575 there were 25 deaths. The fatality rates specific 
for age-group are shown in Table 26.
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. TABLE 26.
Fatality Rates specific for age-group in 857 cases 
of Erysipelas treated with a Sulphonamide Drug.
Age Group 
Tears
Total
Cases
Total
Deaths
Fatality Rate 
per cent.1
0-5 100 10 10
6-10 17 0 0
11-20 81 0 0
21-30 93 0 0
31-40 113 0 0
41-50 180 2 1.1
51-60, 146 4 2.7
61-70 92 3 3-3
7L + 35 6 17.1
Total 857 25 2.9
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The clinical data of the patients who died are summarised in 
Appendix 5> Table 5* These data may be analysed column by column.
(a) Sex. Fourteen of the deaths were in males and eleven in females.
Sex has l i t t le  or no effect upon the outcome.
(b) Age. Most of the cases who died were either under one year or 
over 73 years of age. These groups account for fourteen of the deaths, 
the yopngest a baby of 5 days, the oldest a female of 87 years. It  
will be noted that no death occurred between the ages of two and
forty years. When the natural behaviour of the disease was discussed, i t  
was reported that 80 per cent, of the deaths occurred at ages under 10 
years and over 50 years. The effect of sulphonamide is  to widen this 
gap even further: * in the present series no less than 76 per cent, of 
the deaths occurred under 2 years or over 70 years. When i t  is  remembered 
that, at these ages, in a large proportion of the cases, the erysipelas 
is  a complementary factor of some condition which itse lf carries an 
appreciable mortality risk, the results are all the more gratifying.
(c) Primary- and Recurrent Cases. Only two deaths occurred among those 
who had a history of a previous attack of the disease, which represents 
a fatality rate in this type of case of 1.2 per cent. The fatality  
rate for primary cases of erysipelas is  3*2 per cent. (23 deaths among 
692 cases). The difference (2 per cent.) has a standard error of
± 1.16 so that i t  is  not statistically significant.
(d) Idiopathic and Surgical Cases. The deaths are fa ir ly  evenly
distributed, eleven occurring in idiopathic cases, of which there were
in the series 557 cases. This represents a fatality rate of 1.99 per
*
cent. The rate for surgical cases was 4.7 per cent. The difference /
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difference (2 .7  per cent.) has a standard error o f  +1.35* 80 that i t  i s  
within the leve l o f  s ta tis tica l significance. Such a difference, however, 
might well suggest i t s e l f .  The nsurgicaln conditions which predisposed 
to the attack o f  erysipelas included fungating carcinomas, epitheliomas 
and circumcisions in in fants, so that the higher m ortality in  this type 
o f  case i s  not surprising.
(e) Temperature on admission to hospital. The only point o f  interest 
here i s  to note that the temperature on admission was within normal 
lim its  in  no le ss  than fiv e  patients who subsequently died. I have 
already explained that the absence o f  toxaemia or pyrexia does not 
necessarily indicate a mild case and this finding serves to emphasise 
the point.
( f )  Duration, in days, i l l  prior to admission. In only fiv e  cases who 
subsequently died was the patient admitted la te  in the disease; sixty 
per cent, o f  the deaths reached hospital on the f ir s t ,  second or third 
day o f  illn e ss . I t  may be surmised that many cases admitted la te  in 
the disease had already approached recovery, by natural means.
(g) Duration, in davs. o f  residence in hospital. Three patients died 
within twenty-four hours o f  admission. In a further eight, death was 
in fa ct due to some associated disease or degeneration present prior 
to the onset o f  the erysipelas; and in these eight cases the 
erysipelatous lesion  was healed at the time o f  death.
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The analysis of the fatal cases may be summarised by stating 
that in only two cases could therapy be said to have failed (cases 35^3 
and 3218). Here both patients were less than one year of age and, 
despite chemotherapy, both cases went on to develop a streptococcal 
meningitis. I t  is  worth pointing out that in these very young infants 
vomiting is  not infrequent as a part of the general toxaemia: even apart
from this, administration of the drug to such yodng persons is  difficult, 
and i t  is  often impossible to decide how much is  actually retained.
Both of these infants were poorly nourished and one might argue that 
their resistance to bacterial invasion might on this account be poor. 
Erysipelas has always been a severe infection in this age-group: i t  was
in such infants that "wandering" erysipelas was formerly so frequent.
- To be able to say that in 857 cases of erysipelas only two "failures" 
were noted is  itse lf  a great testimony to the efficacy of the 
sulphonamide group of drugs.
APPENDIX 5*
Results of Chemotherapy with Various Sulphonamide 
Drugs during 193&-1939 inclusive — 7^7 Cases,
TABLE I .
1936.
Sulphonamido--chrysoidine -  106 cases.
Duration, in Days, of Spready, Pyrexia and Toxaemia,
0 1 2 3 4 5 6 7 Over 7
Spread
Pyrexia
1_ 1 
1
r
i 
d
11 
. 
.
36
37
16
37
3
14
1
21
0
5
0 * 
0
0
0
0
0
Toxaemia 6 17 40 23 8 8 2 1 1
Number of Complicated Cases* ..••••••••••lb
Number of Cases showing Relapse  ....................  8
Number of Deaths........................................................  4
These figures refer only to complications which were classified in 
subdivision 3 (see ChapterHI, p. 28. ) , i .e . complications directly 
arising from the inflammatory process.
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APPENDIX 5.
TABLE 2.
1937*
Sulp hon and do- chry soi din e + Ultra-Violet Light . . . . .  54 cases
£- amino-ben zene- sulphon amide .........  135 cases
Total • *••• 189 cases
Duration! in Days, of Spread, Pyrexia and Toxaemia.
0 1 2 3 4 5 6 7 over 7
Spread 98 77 11 2 1 0 0 0 0
PyrexLa 6 71 68 28 10 2 2 0 2
Toxaemia 6 33 56 49 25 12 5 1 2
Number of Complicated Cases 27
Number of Cases shoeing Relapse . . . . .  4
Number of Deaths   6
These figures refer only to complications which were classified in 
subdivision 3 (ChapterHI, p. 28. ) ,  i .e . complications directly 
arising from the inflammatory process.
APPENDIX 5.
1 9 ^ .
Sulphonamido-chrysoidine................................... ................ .
p.-amino-ben zone-sulp hon amide * ................ .
p-benzyl-amino-benzene-sulphonamide . . . . . . . . .
Total
Duration, in Days, o f  Spread, Pyrexia and Toxaemia.
TABLE 3.
60 cases 
122 cases 
60 cases
242 cases
0 1- 2 3 . 4 5 6 7 over 7
Spread 120 80 33 4 - - - - -
Pyrexia 10 77. 91 42 7 4 4 0 0
Toxaemia
- ---------------
2 8 5) 88 79 22 12 0 1
Number o f  Complicated Cases "*■ .   20 -
Number o f  Cases showing Relapse •.. •. 1 case
(chemotherapy 
had been stopped)
Number o f  deaths *   5
These figures refer only to complications which were c lassified  in 
subdivision 3 (see Chapterlll, p. 28. ) ,  i . e .  complications d irectly  
arising from the inflammatory process.
-  100 -
APPENDIX 5.
TABLE 4.
1959.
Sniphonamido-chrysoidine   JL cases
Sulphonami do-chrysoi dine .............. , .  90
Carboxy-sulphonamido-chrysoidine ..................  89
Total . . .  250 cases
Duration, in Days, of Spread, Pyrexia and Toxaemia.
0 1 2 3 4 5 6 7 over 7
Spread 103 106 39 2 0 0 0 0 0
Pyrexia 16 103 100 18 8 2 2 .1 0
Toxaemia 13 30 77 77 33 8 8 2 2
-it-Number of Complicated Cases 
Number of Cases showing Relapse
Number of Deaths
24
1 case
(Chemotherapy- 
had been 
stopped) •
2
^These figures refer only to complications which were classified in 
subdivision 3 (ChapterHI, p. 28. ) , i .e . complications directly arising 
from the inflammatory process.
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CHAPTER VI.
A Study o f  the E ffect o f  Different 
Scales o f  Dosage.
During the end of 1937 the first few months of 193® 811 
Investigation was carried out to try to find, by clinical trial, the 
best dose of the drugs. It was argued that as the main factors of 
assessment (namely, the duration in days of spread, pyrexia and 
toxaemia) had proved valuable in comparing two methods of treatment, 
they might equally well be used to measure the effect of different 
doses of the same drug. Three drugs were used, namely, sulphonamido- 
chrysoidine, in four-hourly doses of 1.0 gramme or 2.0 grammes; 
sulphanilamide, in four-hourly doses of 0.5 gramme, 0.75 gramme,
1.0 gramme or 2.0 grammes; and benzyl-sulphanil amide, in four-hourly 
doses of 1.0 gramme or 2.0 grammes. The last drug was introduced for 
the first time into the investigation. Since I wish in the present 
discussion to focus attention upon the results obtained with the 
different doses of sulphonamido-chrysoidine and sulphanil amide, those 
cases that were given benzyl-sulphanil amide will be omitted. Comparison 
will thereby be simplified and confusion avoided.
The stage was concluded when thirty patients had been admitted to 
each of the six treatment groups. (Two additional patients were entered 
by mistake; both received sulphanil amide, one in doses of 1.0 gramme, 
the other in doses of 2.0 grammes four-hourly). Thus the total number 
of cases should be 182. As we are at present engaged in considering 
the duration in days of spread, pyrexia and toxaemia (factors associated 
with the acute, initial stage of the illness), cases dying within a short 
time of admission cannot be accepted, for in them one or other of the 
factors might not have terminated. Two patients died in the group /
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group receiving sulphonamido-chrysoidine, 2 grammes four-hourly, one vdthin 
24 hours and the other within 48 hours of admission; they have been 
excluded from the analytical tables. The corrected total is , therefore,
180 cases, made up as follows: -
Sulphonamido-chrysoidine, 1 gramme four-hourly . . . . . . .  ^0
11 ” 2 grammes 11 .............  28
Sulphanil amide 0 . 5 ” B ............  30
" 0.75 n * . . . . . . .  30
" i :o  ■ «   31
« 2.0 « »   31
Total ............. 180
The actual duration in days of spread, pyrexia and toxaemia is  shown for
each treatment group in Appendix 6, Tables 1, 2 and 3* Tbe summarised
results vdth the two drugs, irrespective of dosage, are:-
Sulphonamido- Sulphan-
chrysoidine. i l  amide.
Mean Dosage (grammes) 1.48 1.07
Proportion (per cent.) ceasing 
to spread within 24 hours of
admission to hospital   86.2 86.9
Proportion (per cent.) showing 
no fever after 48 hours in
hospital ...........  77.8 72*1
Proportion (per cent.) showing 
no toxaemia after 72 hours
in hospital . . . . .  65.6 59*1
These figures suggest that there is  li t t le  to choos»e between the results 
achieved with the two drugs.
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When the results are separated according to the four-hourly dosage, 
the proportion o f cases in each treatment group ceasing to spread within 
24 hours o f  admission i s  as follow s:—
per cent.
Sulphonamido-chrysoidine 1 grannie ............  80.0
2 grammes . . . . . . .  92*9
Sulphanilamide 0.5 gramme •••...* 7
0.75 gramme .......... . 86. 7
1.0 gramme  ..........  90*3
2.0 grammes ............  93*6
The results obtained with both drugs give the impression that by increasing 
the amount o f  drug we increase the rapidity with which spread ceases.
Clearly the series o f  cases i s  small when subdivided, and the differences 
noted are not outside o f  the lim its o f  error due to random sampling.
The steady advantage o f  increased dosage i s  none the le ss  interesting 
and suggests further scrutiny o f  the figures.
I t  i s  somewhat more d i f f ic u lt  to make an exactly similar comparison 
with regard to the duration o f  pyrexia and toxaemia. Reference to the 
appropriate tables shows that In a small number o f cases pyrexia or 
toxaemia was not present on admission. I have already pointed out that 
there i s  no ju stifica tion  for  labelling  such cases as "mild” ; but their 
inclusion in the proportions might be open to objection. There is ,  
however, no objection to making a comparison between the d ifferent treatment 
groups o f  the proportions in which the factor continued beyond a certa int 
period, namely 48 hours in the case o f  pyrexia and 72 hours in the case 
o f  toxaemia. In order to make, the comparison complete, the percentages 
in which spread, pyrexia or toxaemia continued for  longer than 24, 48 or 
72 hours respectively, in  the six treatment groups, are shown in Table 27.
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TABLE 27.
Proportion (per cent.) of Cases in each Treatment Group 
in which Spread, Pyrexia or Toxaemia continued for more 
than 24, 48 or 72 hours respectively.
Drug: and amount of 
four-hourly dosage 
during acute stage.
per cent, 
continuing 
to Spread 
after 24 hrs. 
in hospital.-
per cent, 
continuing 
Pyrexial 
after 48 hrs. 
in hospital.
per cent, 
continuing 
Toxic after 
72 hrs. in 
hospital.
Sulp hon ami do- 
chrysoidine
1.0 gm. 20.0 I 3.3 * 33-3
2.0 gm. 7.1 32.1 34.0
Sulphanil-
anide
0.5  gm. 23-3 16.6 36.7
0.75 6511* ‘  13.3 26.7 36.0
1.0  gm. 9.7 32.2 42.0
2.0 gm. 6.4 35.5 51.7
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These figures are shown in the form of a graph (Figure 1). The 
trend of the graph suggests that, although an increase in the dose of 
sulphanil amide from 0.5 gramme to 1.0 gramme four-hourly achieved a sharp 
increase in the rate of control of spread, a further increase in the 
amount of drug did not secure an equivalent benefit. I f  this impression 
i s  taken in conjunction with the increased duration of pyrexia and 
toxaemia with greater dosage, one is  justified in concluding that the 
optimum dose of sulphanil amide in cases of erysipelas lie s  between 
0.5 gramme and 1.0 gramme four-hourly. I t  is  a matter of great regret 
that groups of cases were not treated with sulphonamido-chrysoidine in 
doses of 0 .5  gramme and 0.75 gramme, for, although the graph, for this 
drug conveys a similar impression, the number of observations is  too 
small.
In order to analyse the figures further in respect of dose alone, 
the six treatment groups may be collected (irrespective of drug) into 
two broad groups; one which received the lower scales of dosage; and 
the other that which received the higher scales of dosage. The figures 
in Table 28 show that the higher dose of sulphonamides obtained more 
rapid cessation of the spread of the lesion but less rapid abatement 
of pyrexia and toxaemia: a finding which supports the conclusion already
tentatively made. • Moreover, statistical tests would suggest that the 
differences are significant in respect of the duration of spread and 
primary pyrexia.
The data in Table 28 are shown, in the form of cumulative frequency 
distributions, in Figs. 2, 3 and 4.
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THE PROPORTIONS OF CASES (P E R  CENT) IN DIFFERENT 
DOSAGE GROUPS ( SULPHANILAMIDE )  IN WHICH SPREAD, 
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TABLE 28.
A Comparison of the Effects of Low and High Dosage of 
Sulphonamide Drugs.
Factor Scale of Dosage
Duration in Days
0 1 2 3 4 5 6 over 6
Spread
Low Dosage 40 33' 16 i 0 0 0 0
■+”
High Dosage 46 37 7 0 0 0 0 0
Pyrexia
Low Dosage 6 33 37 12 4 0 0 1
High Dosage 4 27 29 18 8 2 2 0
Toxaemia
Low Dosage 1 4 18 36 25 3 3 0
High Dosage 1 2 9 39 31 4 4 0
*  Sulphonamido-chrysoidine 1.0 gm. | combined
Sulphanil amide 0*5 gnu and 0.75 6®* j
^  Sulphonami do-chry soi dine 2.0 gm. £ combined.
Sulphanil amide 1.0 gm. and 2.0 gm. j
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F IG U R E  3 .
THE DURATION IIS DAYS OF PRIMARY PYREXIA IN TWO 
TREATMENT GROUPS ; ONE RECEIVIN G LOW, THE OTHER 
HIGH DOSAGE OF SULPHAN1LAM1DE.
CUMULATIVE FREQUENCY DISTRIBUTION.
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HIGH DOSAGE
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TH E D ISTR IB U TIO N  IN DAYS OF TOXAEM IA IN  TWO  
TREATM ENT G RO U PS THE ONE R E C E IV IN G  LOW , THE  
O T H E R  H IG H  D O S A G E  OF S U L P H A N IL A M ID E  .
CUMULATIVE FREQUENCY DISTRIBUTION.
LOW DOSAGE.
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Discussion,
It has not been easy to show that the optimum therapeutic effect of 
the sulphonamides is  dependent upon the attainment- of a particular 
concentration of the drug in the blood stream. I had not, during the 
present investigations, the advantage of knowing the blood concentrations 
which were attained in my patients. On the other hand, i t  is  clear from 
these present records that a careful clinical survey of the cases permits 
at least a partial answer to the problem. There is  evidence that as the 
oral dose of the drug increases the feature of the disease which reflects 
the activity of the infecting pathogen (namely, spread) is  stemmed more 
effectively. A steady advance in the proportion of cases of erysipelas 
which ceased to show spread of the lesion after twenty-four hours in 
hospital was noted as the dose of sulphaniiamide was increased from 
0*5 gramme four-hourly (3*0 grammes per day) to 2.0 grammes four-hourly 
(12.0 grammes per day); such a result shows that there is  a relationship 
between oral dose and therapeutic effect. This conclusion has been 
further impressed by the subdivision of the cases, irrespective of drug, 
into a low dosage and a high dosage group. The increase in benefit of 
high dosage, so far as cessation of spread is  concerned, is  clear-cut.
A second finding which is  of great importance is  that there is  a 
limit to the benefit which high dosage secures. Increase from 0.5  gramme 
to 0.75 gramme and then to 1.0 gramme of sulphanilamide four-hourly results 
in a clear improvement, but a further increase from 1.0 gramme to 2.0 grammes 
does not show a similar degree of Improvement. Thus in man, there is  
evidence that the relationship between the oral dose of the drug and the 
rapidity of cure is  not a straight line, but a curve. As a result of the /
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the present analysis, i t  is  clear that in the treatment of erysipelas 
the benefit which follows an increase of the dose of drug from 6.0 grammes 
to 12.0 grammes daily is  not great. I t  would be necessary to show that 
this increase in dosage was not accompanied by any deleterious effect 
before such slight therapeutic improvement could be considered of value.
But the figures show just as clearly that beyond a certain point 
a rise in the dose of the drug carries other effects wrhich must be 
regarded as of a toxic nature. For, although high dosage secured improved 
results in respect of the control of spread, i t  undoubtedly prolonged 
the duration of the primary pyrexia. This is  an exceedingly interesting 
finding. When the toxic effects of the drugs are considered, i t  will 
be related that secondary fever, apparently due to the drug, may be 
encountered after a period of normal temperature. Such secondary fever 
usually occurs between the seventh and twelfth day of treatment. I can 
see no fallacy in the present figures which show that the primary pyrexia 
itse lf  was prolonged in those cases that received the high dosage schedule. 
This finding is , to some extent at least, reinforced by the fact that 
in this same high dosage group there is  a suggestive prolongation of the 
period of toxaemia. As I have pointed out in the chapter dealing with 
the methods of the clinical experiment, toxaemia was estimated by noting 
the presence or absence of certain signs or symptoms which usually denote 
a toxic state. Some of these, such as prostration, vomiting and the 
state of the tongue could well be prolonged by a toxic drug: and the
figures produced suggest that such an event may occur when the 
sulphonamides are used in high dosage.
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As a result of the present experiment, therefore, i t  is  possible
to lay down a scheme of dosage for the acute stage of a case of
erysipelas. In patients over the age of ‘five years a dose of between
0.75 gramme and 1.0 gramme four-hourly will secure adequate
therapeutic effect. There is  no good reason to exceed this amount,
%
for when higher dosages are used there is  a danger that the duration 
of primary pyrexia will be prolonged.
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APPENDIX 6.
TABLE I . -
Duration, in Days, o f  Spread o f  Lesion.
Method of Treatment Duration in Days. Total
Drug Dose 0 1 2 3 Cases
. Sulphonamido-
1 gm. 13
(43-3)
11
(36.7)
6
(20. 0)
0 30
chrysoidine. 2 gm. 11
(39.3)
15
(53*8)
2
(7.1)
0 28
0 .5  gm. 13
(43.3)
10
(33.3)
7
(23.3)
0 30
Sulphanil-
amide.
0.75 gm. 14
(46.7)
12
(40.0)
3
(10. 0)
1
(3-3)
30
1 «m# 17
(54.8)
11
(35.5)
3
(9*7)
0 3L
2 gm. 18
(58. 1)
11
(35.5) (6?5)
0 31
Totals 86
(47.5)
10
(39. 1)
23
(12.8)
1
(0 . 5)
180
Note: Recoveries only.
(The figures in brackets are percentages o f  the 
lin e  to ta ls ).
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APPENDIX 6 : TABLE 2.
TABLE 2.
Duration, in Days, of Primary PyrexLa.
Method of Treatment Duration in Days. Total
CasesDrug Dose 0 l 2 3 4 5 6 over
6
1 gnu 1 11 14 3 1 0 0 0 30
Sulphonamido- ( 3- 3) ( 36. 7; (46. 7) (10.0; (3.3)
chrysoidine. 2 gra. 4 8 7 6 1 0 2 0 28
(14- 3) ( 23. 6) (25.0) (21.4 ) ( 3. 6) ( 7.1)
0 .5  gnu 5 8 12 4 1 0 0 0 30
(16.7) (26. 7) (40.0) (13.3) (3. 3)
0.75 ga* 0 11 11 5 2 0 0 1* 3D
Sulphanil­ (36.7) (36. D (16.7) ( 6. 7) (3.3)
amide, 1 gm. 0 11 10 9 0 1 0 0 33-
(35-5) (32.3) (29.0) (3. 2)
2 gm. 0 8 12 3 7 1 0 0 31
(25.8) (38. 7) ( 9. 7) (22.6) (3. 2)
Totals 10
(5-7)
57
(31.6)
66
(29.9)
30
(16.7)
12
(6.6)
2
( l . l )
2
(1.2)
1
(0.6)
1
000rH
The delay here was later shown to be due to drug fever.
Note: * Recoveries only,
(The figures in brackets are percentages of the line 
totals),
>
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table" 3 .
APPENDIX 6 : TABLE 5.
Duration, i n Days, of Toxaemia,
Method of Treatment. Duration in Days. Total 1
Drug Dose 0 1 2 3 4 5 6 over6
Cases
Sulphonami do-
1 gm. 0 0 7
(23. 3)
13
C43.3)
9
(30. 0)
0 1
(3-3)
0 30
chrysoidine. 2 gm.
(3^4) (6?8)
3
(10.2)
12
(40.8)
9
(30. 6)
0
(3-4)
0 28
0.5 gm. 0 4
(13.3)
4
(13.3)
11
(36.7)
8
(26. 7)
2
(6.7) (3-3)
0 30
Sulphanil-
0.75 gm. 1
(3-3)
0 7
(23.1)
12
(39.6)
8
(26.4)
1
(3. 3)
1
(3-3)
0 30
emide. 1 gm. 0 0 3
(9.7) (4^.4)
10
(32. 3)
2
(6. 5) (3-2)
0 31
2 gm. 0 0 3
(9.7)
12
(33.7)
12
(38.7) ( 6. 5) (6?5)
0 31
Totals 2
(1 . 1)
6
(3 . 4)
27
(14.9)
75
(41.3)
56
(30.8)
7
(3-8)
7
(3-8)
0 180
Note; Recoveries only.
(The figures in brackets are percentages of the line totals).
CHAPTER. VII.
Discussion.
-  117 -
The first end second stages of the experiment were conducted at 
the request of the Therapeutic Trials Committee of the Medical Research 
Council: and the reports to this Committee were published in 1937
(Snodgrass and Anderson, 1937* (a)> (b))* Subsequently, papers were 
published which brought the number of cases analysed up to a total of 
824 (Snodgrass, Anderson and Rennie, (1938))* Few reports by others 
have satisfied the conclusions which were reached in the present work 
as a result of the study of the natural behaviour of erysipelas.
Indeed, Mellon, Gross and Cooper (1938) who discussed in some detail 
the published results of the chemotherapy of erysipelas, stated that
"the actual number (of cases of erysipelas treated with sulphonamides)....
cannot be estimated because some authors, apparently quoting from 
extensive experience, were satisfied to illustrate their clinical results 
by presenting only two or three typical examples end failed to indicate 
the number of treated cases coming under their observation. n The 
same workers compiled a table which listed thirty-nine reports of the 
treatment of erysipelas with sulphonamide compounds. In no less than 
twenty-four of these the number of cases dealt with did not exceed twenty: 
and in only two of them (apart from my own) was the number over a hundred. 
Bloch^Michel, Conte and Durel (1936), i t  is  true, reported a series of
977 cases — all treated with a sulphonamide but with no concurrent 
control — in which there were only nine deaths. The fatality rate
for those over 69 years of age was 12 per cent.; under the age of 2J- years
the rate was 6.5 per cent. These are undoubtedly satisfactory rates:
but there is  an absence of data which would allow an assessment by the
reader of the true efficacy of the drug, since other cases were not /
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not given, during the same period of time, an alternative method of
treatment. The results which I obtained in those cases which received
"sugar of milk” show very clearly that erysipelas is  an exceedingly
wayward disease: and that there is  no accurate method by which one can
assess the severity of a particular case. In a disease such as this
the method of clinical trial must satisfy certain demands. A very
large series of cases must be reviewed; there must be concurrent control 
/
of the new treatment by some other generally accepted method of treatment; 
and an attempt must be made to establish criteria of cure other than the 
simple one of recovery or death. It is submitted that these desiderata 
have been met in the therapeutic investigation, the results of which I 
have now reported.
It  should, too, be emphasised that in recording and analysing these 
results, any repetition or continued re-examination of the figures has been 
intentional. The history of the treatment of erysipelas is  marked by a 
succession of claims for effective methods of treatment which later 
experience has shown to be without foundation. No longer ago than I 928 
Symmers claimed that the introduction of specific antitoxic treatment 
in erysipelas "marked an advance whose results were only commensurate 
with those obtained by the antitoxic treatment of diphtheria." My own 
experience with antitoxic treatment has been less impressive (Anderson, 
1939)* It has seemed to me, therefore, to be a wise precaution to 
examine and re-examine the figures in the present analysis so that there 
might be no mistake made in their assessment.
It  /
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It  is  clearly shown that the sulphonamides are an exceedingly 
effective method of treatment. In nine cases out of ten, spread — the 
clearest manifestation of activity — can be arrested within twenty- 
four hours of starting the drug. This is  followed, twenty-four to 
forty-eight hours later, by the cessation of fever and toxaemia.
Further, when the drugs are given over the period of convalescence, 
relapse (previously a common feature of the disease) becomes unusual.
In one respect the results are perhaps disappointing, namely, 
that the reduction in those complications directly due to the presence 
of streptococci in the body is  not greater. This finding is  in itse lf  
interesting. Many of these complications are of a pyogenic nature, and 
their continuation in cases which received sulphonamides suggests that 
the drugs are ineffective in preventing pus formation or in clearing the 
complication when pus has accumulated. Okell (1932) suggested that 
the streptococcus has three main attacking properties, namely, the 
ability to produce an exo toxin — the ery thro genic toxin —,a  capacity 
of invasiveness, and thirdly pyogenicity. French (1939) wh° carried out 
her work under my guidance was unable to show that the sulphonamide drugs 
had any beneficial effect upon the outcome of cases of scarlet fever.
Now the clinical type of scarlet fever prevalent in the City of Glasgow 
during the last ten years is  mild. The one feature which is  constantly 
present, and which gives the disease its  name, is  the generalised 
erythematous eruption, due to the rash-producing toxin. The disease is , 
.in fact, in many respects similar to diphtheria,in that there is  a 
diffusion throughout the body of a toxin which is  produced locally in 
the throat. Actual invasion of the tissues by the streptococcus is  /
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is  less frequent; but pyogenicity (e.g. suppurative adenitis) is  
somewhat commoner, although even this aspect is  today unusual* The 
administration of the sulphonamides to cases of scarlet fever produced 
no effect upon the toxic element or on the pyogenic element.
French (Ibid.) showed for example that the duration of the rash was 
unaffected by the administration of the sulphanil amide; and that 
such complications as suppurative otitis media and cervical adenitis 
occurred as frequently in the sulphanil amide-treated group as in 
the controls.
In puerperal fever and in erysipelas, on the other hand, the 
elaboration and general diffusion of the rash-producing toxin is  as a 
rule not apparent. In other words, either the infecting streptococcus 
is  lacking in this capacity, or the patient is  immune to its  effect.
In both diseases, however, invasiveness and pyogenicity are the 
features of the streptococcus which are paramount. For example, in 
puerperal fever, the occurrence of septicaemia has always been 
considered of the greatest prognostic value; in the past its  
occurrence was usually a prelude to a fatal termination. Pyogenicity 
in these diseases is  variable in its  occurrence, but common enough 
in both.
The fact that sulphonamides are effective in puerperal fever 
(Colebrook and Kenny, 193^ ) erysipelas, end apparently ineffective 
in scarlet fever, suggests very strongly that their action is  certainly 
not concerned with the neutralisation of the erythrogenic toxin. The 
facts that, in erysipelas, the incidence of pyogenic complications is
/
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is  s t i l l  considerable, 8nd that the main action of the drugs seems to 
be in limiting the spread of the local lesion, strongly favour a view 
that the action of the drugs is  anti-invasive in character; that in 
some way they interfere with the invasiveness of the infecting 
organism, thus enabling the host to complete its  destruction.
Such a view is  in keeping with the observed clin ical facts in 
respect of the occurrence of complications. But i t  may also explain 
the observation that a complete correlation of dose and clinical effect 
could not be demonstrated. I f the action of the drugs is  to 
inhibit "invasiveness1’, then the effective dose will be dependent 
upon other factors as important as the actual concentration in the 
blood of the active drug. firs t, the host’ s innate ability to cope 
with the infecting organism will be of major importance. I f his 
defences are good, then a l i t t le  assistance from the drug will be 
a ll that is  required; but i f  his defences are poor or deficient, then 
even optimal concentrations of the drug may be useless for he may be 
unable to cope even with the denatured organism. On the other hand, 
i t  is  not hard to imagine that the streptococci themselves w ill vary
considerably in their invasive capacity. With some, whose powers 
are slight, small amounts of the drug may well suffice so to 
impoverish the organism that the host finds i t  an easy antagonist.
With others, the invasive capacity may be so great as to place them 
beyond the power of the drug.
Such /
Such a view> i t  may be argued, does not carry us veiy far.
But is  does serve to emphasise the point that, effective as the 
sulphonamides undoubtedly are, their effect is  limited. This 
limitation may depend upon three factors, first, the general 
defensive capacity of the host; second, the offensive capacity of
the invading organism; and finally, the achievement of the required 
concentration of the active antibacterial substance in the body.
The present tendency is  to lay emphasis upon the second and third 
factors, almost to the exclusion of the first. Later, when the 
results of the treatment of pneumonia are discussed, a return vdll 
be made to this point.
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